- Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2012 - Conditions: Colitis,Ulcerative; Adenomatous Polyposis Coli; Reservoir, Ileoanal
Intervention:
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Recruiting - verified March 2012 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012 - Condition: Anal Fistula
Intervention: Biological: reinforce soft tissue
Sponsors: Cook; Cook
Not yet recruiting - verified May 2012 - Condition: Pancreatic Neuroendocrine Cancer
Intervention: Other: MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012 - Condition: Hepatic Impairment
Intervention: Drug: telaprevir
Sponsors: Janssen Infectious Diseases BVBA; Janssen Infectious Diseases BVBA
Not yet recruiting - verified May 2012 - Condition: Chronic Liver Disease
Intervention: Drug: Perfusion MRI (adofosveset trisodium, Ablavar, Lantheus)
Sponsors: Mount Sinai School of Medicine; Bachir Taouli
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Intervention: Procedure: Liver resection plus Thrombectomy
Sponsors: Sun Yat-sen University; Sun Yat-sen University; Guangzhou Eight People's Hospital; Kaiping central hospital; The 458 Hospital of Chinese People's Liberation Army
Completed - verified May 2012 - Condition: Fecal Incontinence
Intervention: Biological: AMDC
Sponsors: Cook; Cook
Recruiting - verified May 2012 - Condition: Parenteral Nutrition Associated Cholestasis
Intervention: Drug: Omegaven
Sponsors: University of California, Davis; University of California, Davis
Enrolling by invitation - verified May 2012 - Conditions: Colorectal Cancer; Dysgeusia; Oral Complications of Chemotherapy
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Biological: bovine lactoferrin
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Conditions: Encephalopathy, Hepatic; Cerebrovascular Disorders; Liver Failure
Intervention: Other: No interventions
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Entecavir + Tenofovir (MDR group)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital
Not yet recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Behavioral: Risk Assessment
Sponsors: Boston Medical Center; Boston Medical Center
Enrolling by invitation - verified April 2012 - Condition: Hepatic Impairment
Intervention: Drug: LCQ908
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Non-small Cell Lung Cancer; Pancreatic Cancer
Intervention: Drug: Epidermal growth factor (EGF) ointment
Sponsors: Dong-A University Hospital; Dong-A University Hospital
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Mirtazapine plus gemcitabine; Drug: Gemcitabine, placebo
Sponsors: Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting - verified May 2012 - Condition: Lactose Malabsorption
Interventions: Dietary Supplement: Acid lactase; Dietary Supplement: Acid lactase; Dietary Supplement: Lyoph. yoghurt bacteria; Dietary Supplement: Acid lactase plus yoghurt bacteria; Dietary Supplement: Placebo
Sponsors: Vitacare Gmbh & Co. KG; Vitacare Gmbh & Co. KG
Completed - verified May 2012 - Conditions: HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Other: Blood analysis by EPISPOT and Cellsearch
Sponsors: University Hospital, Montpellier; University Hospital, Montpellier; National Cancer Institute, France; Direction Générale de l'Offre de Soins; Roche Pharma AG
Recruiting - verified May 2012 - Conditions: Constipation; Faecal Impaction
Interventions: Drug: Polyethylene glycol with electrolytes; Device: Polyethylene glycol
Sponsors: Azienda Policlinico Umberto I; Azienda Policlinico Umberto I; Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Completed - verified May 2012 - Condition: Environmental Enteropathy
Interventions: Dietary Supplement: Fish oil and micronutrients; Dietary Supplement: Micronutrient Supplement; Drug: Placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Enrolling by invitation - verified May 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: NHO - Matsumoto Medical Center; NHO - Matsumoto Medical Center
Completed - verified May 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: BKM120; Drug: Panitumumab
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Not yet recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Other: FDG PET-CT; Other: Diffusion MRI
Sponsors: Jules Bordet Institute; Jules Bordet Institute
Not yet recruiting - verified February 2012 - Condition: Functional Dyspepsia
Intervention:
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City
Recruiting - verified May 2012 - Condition: Gastric Cancer
Interventions: Drug: Onartuzumab; Drug: Placebo; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Conditions: Fatigue; Nausea and Vomiting; Pain; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage I-IVB Colon Cancer; Stage I-IVB Rectal Cancer
Interventions: Procedure: Yoga therapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Other: assessment of therapy complications; Procedure: management of therapy complications; Other: educational intervention
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified May 2012 - Condition: Pancreatic Carcinoma Non-resectable
Intervention: Radiation: Induction Chemotherapy with CCRT
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified May 2012 - Condition: Inflammatory Bowel Diseases
Intervention: Other: Salivary samples
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified April 2012 - Condition: Gastrointestinal Diseases
Intervention: Biological: EVICEL
Sponsors: Ethicon, Inc.; Ethicon, Inc.
Not yet recruiting - verified April 2012 - Condition: Hepatitis B
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620; Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Other: Neuroimaging & Neuropsychological Evaluation; Other: Neuroimaging & Neuropsychological Evaluation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Sun Yat-sen University; Sun Yat-sen University
Completed - verified May 2012 - Condition: Locally Advanced Rectal Cancer
Interventions: Drug: veliparib; Drug: capecitabine; Radiation: radiation
Sponsors: Abbott; Abbott
Not yet recruiting - verified March 2012 - Conditions: The Primary Study Objective is to Assess the Efficacy and; Safety of Extended 4-week Heparin Prophylaxis Compared to; Prophylaxis Given for 8±2 Days After Planned Laparoscopic; Surgery for Colorectal Cancer.; The Clinical Benefit Will be Evaluated as the Difference in; the Incidence of VTE or VTE-related Death Occurring Within 30 Days; From Surgery in the Two Study Groups.
Intervention: Drug: Heparin, Low-Molecular-Weight
Sponsors: University Of Perugia; University Of Perugia
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: XELOX; Drug: bevacizumab [Avastin]; Drug: mFOLFOX6; Drug: bevacizumab [Avastin]; Drug: FOLFIRI
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Conditions: Low Anterior Resection Syndrome; Rectal Cancer
Intervention: Drug: intra-rectal Botulinum toxin A injection
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Allergan
Not yet recruiting - verified June 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Cyclophosphamide; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine; Radiation: Stereotactic Body Radiation (SBRT); Drug: FOLFIRINOX
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified May 2012 - Condition: Crohns Disease
Interventions: Procedure: MRE (magnetic resonance enterography); Procedure: The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse); Behavioral: Study Questionnaires
Sponsors: University of Michigan; University of Michigan
Recruiting - verified April 2012 - Condition: Inflammatory Bowel Disease
Intervention: Drug: Iron Isomaltoside 1000
Sponsors: Pharmacosmos A/S; Pharmacosmos A/S; Max Neeman International; Pharma Consulting Group
Not yet recruiting - verified May 2012 - Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PBConditions: Pancreatic Cancer; Biliary Tract Cancer; Cancer Pain; Depression
Intervention: Other: Early Palliative care integrated with usual oncologic care
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified April 2012 - Condition: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Interventions: Biological: Ipilimumab; Other: Best Supportive care (BSC)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Rectal Cancer
Interventions: Procedure: TME; Procedure: TME; Procedure: Neuromonitoring
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz
Not yet recruiting - verified April 2012 - Condition: Pancreatic Cancer
Intervention: Drug: Norzyme
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea; Pharmbio Korea Co., Ltd.
Recruiting - verified April 2012 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Pancreatic Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Conditions: Anal Fistula; Fecal Incontinence; Surgery
Intervention: Procedure: Gore-BioA fistula plug
Sponsors: Central Finland Hospital District; Central Finland Hospital District
Recruiting - verified April 2012 - Conditions: Cancer Survivor; Breast Cancer; Colorectal Cancer; Gynecological Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Behavioral: Mindfulness Based Cancer Recovery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2012 - Conditions: Cervical Cancer; Oropharyngeal Cancer; Vaginal Cancer; Anal Cancer; Penile Cancer
Interventions: Drug: Fluderabine; Drug: Cycolphosphamide; Biological: Young TIL; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Colonic Neoplasms
Intervention: Behavioral: Behavioral Intervention
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Metastatic Pancreas Cancer
Interventions: Drug: 5FU, leucovorin, oxaliplatin; Drug: Gemcitabine
Sponsors: Alberta Health Services; Alberta Health Services
Not yet recruiting - verified April 2012 - Condition: Extremely Complex Perianal Fistulae
Intervention: Drug: Adipose-derived stem cells without expanded
Sponsors: Instituto de Investigación Hospital Universitario La Paz; Instituto de Investigación Hospital Universitario La Paz
Recruiting - verified April 2012 - Conditions: Primary Bile Acid Malabsorption; Secondary Bile Acid Malabsorption; Chronic Diarrhoea
Intervention: Drug: Obeticholic acid
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified April 2012 - Conditions: Retroperitoneal Fibrosis; Autoimmune Pancreatitis; Sialadenitis; Pseudotumor
Intervention: Drug: Rituximab
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Genentech
Recruiting - verified April 2012 - Condition: Rectal Cancer
Intervention: Drug: Amifostine
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: Gastric Cancer
Intervention: Procedure: Laparoscopy-assisted total gastrectomy
Sponsors: Soonchunhyang University Hospital; Soonchunhyang University Hospital
Not yet recruiting - verified April 2012 - Condition: Gallstone Disease
Intervention: Procedure: Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy
Sponsors: Cantonal Hosptal, Baselland; Cantonal Hosptal, Baselland
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer
Intervention:
Sponsors: Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Surrey
Recruiting - verified April 2012 - Condition: Levator Ani Syndrome
Interventions: Drug: Nifedipine; Drug: Placebo Ointment Base
Sponsors: Vanderbilt University; Vanderbilt University
Not yet recruiting - verified April 2012 - Condition: Rectal Neoplasms
Interventions: Drug: capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Interventions: Drug: FOLFIRINOX; Drug: Capecitabine; Radiation: Proton Radiation; Procedure: Surgery
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Conditions: Metastatic Cancer; Pancreatic Cancer; Mesothelioma
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Crohns Disease
Intervention: Drug: Certolizumab
Sponsors: Baylor College of Medicine; Baylor College of Medicine; UCB, Inc.
Recruiting - verified April 2012 - Condition: Rectal Cancer
Intervention:
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: Acute and Chronic Hepatic Failure With Developing Coma
Intervention:
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified April 2012 - Condition: Esophageal Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel plus 5-fluorouracil; Drug: Cisplatin plus 5-fluorouracil; Radiation: Radiation therapy; Radiation: Radiation therapy
Sponsors: Fudan University; Fudan University
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Procedure: Warm Water Immersion Colonoscopy; Procedure: Cool Water Immersion Colonoscopy
Sponsors: Vitkovice Hospital; Vitkovice Hospital
Not yet recruiting - verified April 2012 - Conditions: Liver Cancer; Pancreatic Cancer
Interventions: Drug: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin); Device: TheraSpheres
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Nordion (Canada) Inc.
Recruiting - verified April 2012 - Conditions: Carcinoma of the Appendix; Primary Peritoneal Cavity Cancer
Interventions: Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery; Other: quality-of-life assessment; Drug: hyperthermic intraperitoneal chemotherapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2009 - Condition: Colorectal Cancer
Intervention:
Sponsors: Epigenomics, Inc; Epigenomics, Inc
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Intervention:
Sponsors: University of Oklahoma; University of Oklahoma
Enrolling by invitation - verified April 2012 - Conditions: Cholestasis; Psychomotor Disorders, Developmental
Interventions: Drug: mixed lipid emulsion containing fish oil; Drug: Soy bean based lipid emulsion
Sponsors: Medical University of Vienna; Medical University of Vienna
Not yet recruiting - verified January 2012 - Condition: Sitosterolemia
Intervention: Drug: Ezetimibe
Sponsors: University of Manitoba; University of Manitoba
Recruiting - verified April 2012 - Conditions: Pharmacokinetics; Healthy Subjects; Mild and Moderate Hepatic Impairment
Intervention: Drug: mirabegron
Sponsors: Astellas Pharma Inc; Astellas Pharma Europe BV
Completed - verified April 2012 - Conditions: Rectal Cancer; Adenocarcinoma
Intervention: Procedure: Single Incision Laparoscopic Surgery
Sponsors: Hvidovre University Hospital; Hvidovre University Hospital
Recruiting - verified April 2012 - Condition: Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
Interventions: Drug: AZD8931; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Erosive Gastritis
Interventions: Drug: Placebo; Drug: SK-MS10; Drug: SK-MS10
Sponsors: SK Chemicals Co.,Ltd.; SK Chemicals Co.,Ltd.
Recruiting - verified December 2010 - Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Doxorubicin-EMCH
Sponsors: CytRx; CytRx
Not yet recruiting - verified May 2012 - Condition: Crohn's Disease
Interventions: Drug: Azithromycin + Metronidazole; Drug: Metronidazole
Sponsors: Wolfson Medical Center; Prof. Arie Levine
Not yet recruiting - verified May 2012 - Condition: Colorectal Neoplasms
Intervention: Biological: Samples and follow up
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified April 2012 - Condition: Rectal Cancer
Interventions: Other: VSL#3; Other: Placebo
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified April 2012 - Condition: Gastroesophageal Reflux Disease
Intervention: Device: EndoStim LES Stimulation System
Sponsors: EndoStim Inc.; EndoStim Inc.
Recruiting - verified April 2012 - Conditions: Rheumatoid Arthritis; Crohn's Disease
Intervention:
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2012 - Conditions: Gastroesophageal Reflux Disease; Gastritis
Intervention: Other: Histological analysis
Sponsors: Medical University of Graz; Medical University of Graz
Recruiting - verified April 2012 - Conditions: Acute Diarrhea; Acute Gastroenteritis
Interventions: Drug: Racecadotril; Other: Placebo
Sponsors: Centro Pediatrico Albina de Patino; Centro Pediatrico Albina de Patino
Completed - verified June 2011 - Condition: Crohn's Disease
Intervention: Biological: Trichuris suis ova (TSO)
Sponsors: Coronado Biosciences, Inc.; Coronado Biosciences, Inc.
Not yet recruiting - verified April 2012 - Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Vitamin D Deficiency; Hepatocellular Carcinoma
Interventions: Drug: Vitamin D3 4000 IU; Drug: Vitamin D3 2000 IU
Sponsors: Mount Sinai School of Medicine; Andrea Branch
Recruiting - verified April 2012 - Conditions: GERD; Obesity
Intervention: Behavioral: Self support, group sessions, meal replacement therapy
Sponsors: Kansas City Veteran Affairs Medical Center; Kansas City Veteran Affairs Medical Center; Midwest Biomedical Research Foundation
Recruiting - verified April 2012 - Conditions: Epidermoid Carcinoma; Anus
Interventions: Drug: radiochemotherapy; Drug: Panitumumab
Sponsors: Federation Francophone de Cancerologie Digestive; Federation Francophone de Cancerologie Digestive
Not yet recruiting - verified April 2012 - Condition: Crohn's Disease
Intervention: Other: Pilcam colon capsule and PillCam™ Prep Procedure
Sponsors: Given Imaging Ltd.; Given Imaging Ltd.
Active, not recruiting - verified April 2012 - Condition: Cirrhosis of the Liver
Intervention:
Sponsors: Northwestern University; Northwestern University; Loyola University
Recruiting - verified April 2012 - Condition: Porphyria Cutanea Tarda
Interventions: Drug: Hydroxychloroquine; Procedure: Phlebotomy
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified April 2012 - Conditions: Intestinal Failure; Short Bowel Syndrome
Interventions: Drug: Glucagon-Like Peptide 2; Drug: Glucagon like peptide-2
Sponsors: Alberta Children's Hospital; Alberta Children's Hospital; Stollery Children's Hospital; The Hospital for Sick Children; Children's & Women's Health Centre of British Columbia
Recruiting - verified April 2012 - Condition: Gastric Tumor
Intervention: Procedure: CO2 or room air insufflation during colonoscopy or ESD for gastric tumor
Sponsors: Gachon University Gil Medical Center; Gachon University Gil Medical Center
Not yet recruiting - verified April 2012 - Condition: Gastric Carcinoma
Interventions: Drug: Tesetaxel; Drug: Placebo; Drug: Capecitabine
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified April 2012 - Conditions: Barrett's Esophagus; Gastroesophageal Reflux Disease
Intervention:
Sponsors: Kansas City Veteran Affairs Medical Center; Kansas City Veteran Affairs Medical Center
Not yet recruiting - verified April 2012 - Conditions: Barrett's Esophagus; Gastroesophageal Reflux Disease
Intervention:
Sponsors: Kansas City Veteran Affairs Medical Center; Kansas City Veteran Affairs Medical Center
Recruiting - verified April 2012 - Conditions: Cystic Fibrosis; Chit1
Intervention:
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Completed - verified April 2012 - Conditions: Barrett's Esophagus; Esophageal Neoplasms
Interventions: Device: Radiofrequency Ablation(RFA) by HALO device.; Device: Endoscopic mucosal resection(EMR) by mucosectomy kit.
Sponsors: Kansas City Veteran Affairs Medical Center; Kansas City Veteran Affairs Medical Center; American Society for Gastrointestinal Endoscopy; Cook Incorporated; Washington University School of Medicine; Columbia University; University of Chicago
Recruiting - verified April 2012 - Condition: Gastric Adenocarcinoma
Interventions: Drug: Oxaliplatin+S-1; Drug: Adjuvant Oxaliplatin/S-1（SOX）
Sponsors: Chinese PLA General Hospital; Lin Chen
Recruiting - verified April 2012 - Condition: Hepatitis C Virus Infection, Response to Therapy of
Intervention: Behavioral: Personalized Physical Activity and Psycho-Education (PPAPE) Program
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Health Research Institutes, Taiwan
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention: Behavioral: muscular strength
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified May 2012 - Condition: Crohn's Disease
Intervention: Behavioral: Questionnaire
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012 - Condition: Pediatric Crohn's Disease
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified April 2012 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: AFLIBERCEPT AVE0005; Drug: FOLFIRI
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Not yet recruiting - verified April 2012 - Conditions: Healthy; Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions: Drug: dacomitinib; Drug: dacomitinib; Drug: dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Acute Diarrhea; Acute Gastroenteritis
Interventions: Drug: Zinc Sulfate; Other: placebo
Sponsors: Centro Pediatrico Albina de Patino; Centro Pediatrico Albina de Patino
Recruiting - verified June 2011 - Conditions: Adenocarcinoma, Scirrhous,; Linitis Plastica; Stomach Neoplasms,; Stomach Diseases,; Neoplasms by Site; Neoplasms
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Gastroesophageal Reflux Disease (GERD)
Interventions: Device: 24 hour ambulatory pH study; Procedure: Upper endoscopy
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Crohn's Disease
Interventions: Drug: cyclophosphamide; Radiation: total-body irradiation; Drug: mycophenolic acid enteric coated; Drug: tacrolimus; Other: quality-of-life assessment; Other: laboratory biomarker analysis; Drug: fludarabine phosphate; Procedure: allogeneic bone marrow transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center
Not yet recruiting - verified April 2012 - Condition: Chronic HCV-related Hepatitis
Interventions: Dietary Supplement: Coffee; Dietary Supplement: coffee abstinence
Sponsors: Azienda Ospedaliera di Padova; Azienda Ospedaliera di Padova
Completed - verified April 2012 - Conditions: Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: National University Hospital, Singapore; National University Hospital, Singapore
Recruiting - verified April 2012 - The Feasibility and Safety of a Three-Port Laparoscopic Cholecystectomy Using a 2-mm Mini-InstrumentCondition: Gallbladder Disease
Intervention: Procedure: 2- mini-instrument
Sponsors: Inje University; Inje University
Completed - verified April 2012 - Conditions: Colorectal Cancer Stage 0; Colorectal Cancer Stage I; Colorectal Cancer Stage II; Colorectal Cancer Stage III; Colorectal Cancer Stage IV
Intervention: Procedure: colonic or colorectal resection
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Completed - verified March 2012 - Condition: Crohn's Disease
Intervention: Device: vagus nerve stimulation (VNS)
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble; Institut National de la Santé Et de la Recherche Médicale, France; Université Joseph Fourier; CRSSA : Centre Recherche Service Santé Armée
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: Vitamin D3 (cholecalciferol); Drug: Placebo
Sponsors: University of Illinois; University of Illinois
Completed - verified April 2012 - Condition: Colorectal Cancer.
Intervention: Radiation: Stereotactic body radiotherapy
Sponsors: Sunnybrook Health Sciences Centre; Dr. Yoo-Joung Ko; Roche Pharma AG
Recruiting - verified April 2012 - Condition: Advanced Cancer
Interventions: Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Intervention: Drug: Metformin
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified March 2012 - Conditions: Severe Sepsis; Pancreatitis; Abdominal Abscess; Appendicitis; Digestive System Fistula
Interventions: Drug: Norepinephrine; Procedure: Open abdomen; Other: enteral nutrition; Other: parenteral nutrition
Sponsors: Jinling Hospital, China; Jinling Hospital, China
Completed - verified April 2012 - Conditions: Anal Cancer; Cervical Cancer; Lung Cancer; Lymphoma; Nonneoplastic Condition
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Inhaled GSK573719/vilanterol; Drug: Inhaled GSK573719
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Colonic Diseases; Stricture; Occlusion
Intervention: Device: Fully covered metallic colonic stent
Sponsors: Société Française d'Endoscopie Digestive; Société Française d'Endoscopie Digestive
Completed - verified March 2012 - Conditions: Leukemia; Lymphoma; Small Intestine Cancer
Interventions: Drug: alisertib; Drug: vorinostat; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: flow cytometry; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Cancer Screening
Interventions: Behavioral: Best clinical practices plus culturally targeted print materials; Behavioral: Best clinical practices plus standard print materials; Behavioral: Best clinical practices alone
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Memorial Sloan-Kettering Cancer Center
Enrolling by invitation - verified March 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Other: blood samples
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting - verified April 2012 - Conditions: Early Detection of Cancer; Colon Cancer; Decision Making; Patient-Centered Care
Interventions: Behavioral: Making A Decision About CRC Screening; Behavioral: Drivers 65 Plus
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Duke University; Agency for Healthcare Research and Quality (AHRQ)
Enrolling by invitation - verified April 2012 - Condition: Barrett's Esophagus
Intervention: Genetic: response to therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Celiac Disease; Irritable Bowel Syndrome
Intervention:
Sponsors: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis; Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Enrolling by invitation - verified April 2012 - Conditions: Poliomyelitis; Tropical Enteropathy
Intervention: Biological: Oral vaccines (OPV and rotavirus vaccine) and IPV
Sponsors: International Vaccine Institute; International Vaccine Institute; Bill and Melinda Gates Foundation; National Institute of Cholera and Enteric Diseases, India; University of Virginia; University of Vermont
Recruiting - verified April 2012 - Conditions: Symptomatic Venous Thromboembolism; Asymptomatic Venous Thromboembolism
Intervention: Procedure: CRC surgery
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Recruiting - verified March 2012 - Condition: Barrett's Esophagus
Interventions: Drug: Omeprazole; Drug: Melatonin
Sponsors: Aragon Institute of Health Sciences; Aragon Institute of Health Sciences
Not yet recruiting - verified March 2012 - Conditions: Celiac Disease; Diabetes Mellitus, Type 1
Intervention: Dietary Supplement: Gluten Free Diet
Sponsors: The Hospital for Sick Children; The Hospital for Sick Children
Active, not recruiting - verified March 2012 - Condition: Dysphagia
Intervention: Behavioral: Isometric Progressive Resistance Oropharyngeal Therapy
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Not yet recruiting - verified March 2012 - Condition: Colorectal Cancer With Liver Metastasis
Intervention: Procedure: perihepatic lymphadenectomy
Sponsors: Gachon University Gil Medical Center; Gachon University Gil Medical Center
Recruiting - verified March 2012 - Condition: Gastric Adenocarcinoma
Interventions: Drug: Docetaxel; Drug: Fluorouracil
Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University; Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting - verified March 2012 - Conditions: Liver Diseases; Liver Neoplasms; Hepatic Haemangioma
Interventions: Procedure: intrahepatic Glisson's approach; Procedure: classical hepatectomy
Sponsors: Southwest Hospital, China; Shuguo Zheng, MD
Enrolling by invitation - verified March 2012 - Condition: Total Parenteral Nutrition-induced Cholestasis
Interventions: Drug: Soybean oil based emulsion; Drug: Soybean oil based emulsion+Fish oil based emulsion
Sponsors: University Health Network, Toronto; University Health Network, Toronto; ASPEN Rhoads Research Foundation; Fresenius Kabi; University of Alberta; Foothills Medical Centre; St. Boniface General Hospital Research Centre; Hamilton Health Sciences Corporation; St. Paul's Hospital, Canada
Recruiting - verified February 2012 - Condition: Gastrointestinal Neoplasms
Interventions: Drug: Everolimus; Drug: octeotride LAR
Sponsors: Grupo Espanol de Tumores Neuroendocrinos; Grupo Espanol de Tumores Neuroendocrinos
Recruiting - verified April 2012 - Conditions: Colorectal Neoplasms; Neoplasm Metastasis; Liver Neoplasms
Interventions: Drug: Cetuximab; Drug: chemotherapy of FOLFOX or FOLFIRI
Sponsors: Fudan University; Xu jianmin
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: Oxaliplatin; Drug: Irinotecan
Sponsors: Sun Yat-sen University; Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University
Not yet recruiting - verified March 2012 - Condition: Hepatic Impairment
Intervention: Drug: BAF312
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Conditions: Liver Failure; Acute Kidney Disease; Multi-organ Failure
Interventions: Device: Continuous renal replacement therapy (CRRT); Procedure: Standard intraoperative support
Sponsors: University of Alberta; University of Alberta
Not yet recruiting - verified April 2012 - Conditions: Benign Neoplasm of Intestinal Tract; Primary Malignant Neoplasm of Intestinal Tract; Secondary Malignant Neoplasm of Intestinal Tract
Interventions: Procedure: Normal fluid volume; Procedure: Reduced fluid volume
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Recruiting - verified March 2012 - Conditions: Fontan Physiology Patients With PB or PLE; Fontan Physiology Patients Without PB or PLE
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin
Not yet recruiting - verified March 2012 - Conditions: Hepatic Impairment; Healthy
Intervention: Drug: Bardoxolone Methyl
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Other: new norwegian food based dietary guidelines
Sponsors: University of Oslo; University of Oslo; Oslo University Hospital; National Institute for Health and Welfare, Finland; University Hospital, Akershus; Asker & Baerum Hospital; Sykehuset Buskerud HF; Norwegian Cancer Society; The Research Council of Norway
Recruiting - verified March 2012 - Conditions: Acquired Bleeding Disorder; Chronic Liver Disease
Interventions: Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012 - Conditions: Gastroesophageal Reflux Disease; Gastro-oesophageal Reflux; Gastro-Esophageal Reflux; Esophageal Reflux; GERD
Intervention:
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Completed - verified May 2012 - Conditions: Acquired Bleeding Disorder; Cirrhosis
Interventions: Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012 - Condition: Gastroesophageal Reflux Disease
Intervention: Device: EndoStim LES Stimulation System
Sponsors: EndoStim Inc.; EndoStim Inc.
Recruiting - verified April 2012 - Conditions: Pancreatic Cyst; Pancreatic Neoplasms; Pancreatic Adenoma; Pancreatic Cancer; Pancreatic Islet Cell Tumors; Lymph Node; Lymphadenopathy
Interventions: Procedure: EUS-FNA; Device: nCLE
Sponsors: Mauna Kea Technologies; Mauna Kea Technologies
Not yet recruiting - verified May 2012 - Conditions: KRAS Mutated Colorectal Adenocarcinoma.; Metastatic Pancreatic Adenocarcinoma; BRAF Mutated Melanoma
Intervention: Drug: MEK162 + AMG 479
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Celiac Disease
Intervention:
Sponsors: Alvine Pharmaceuticals Inc.; Alvine Pharmaceuticals Inc.
Recruiting - verified April 2012 - Condition: Pediatric Inflammatory Bowel Disease
Intervention: Drug: Gut microbial transplantation
Sponsors: Spectrum Health Hospitals; Spectrum Health Hospitals
Recruiting - verified March 2012 - Conditions: Gastro-esophageal Reflux Disease; Non-erosive Reflux Disease
Intervention:
Sponsors: Maharaj Nakorn Chiang Mai Hospital; arpa pungrasamee
Completed - verified March 2012 - Conditions: Blood, Injection, Injury Type Phobia; Gastrointestinal Ulcer Haemorrhage; Adverse Reaction to Epinephrine
Interventions: Drug: Epinephrine; Biological: Blood
Sponsors: Zagazig University; Zagazig University
Recruiting - verified March 2012 - Condition: Hepatitis B
Intervention: Other: Renal Safety Surveillance
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Epigenomics, Inc; Epigenomics, Inc; Kaiser Permanente; Emory University
Not yet recruiting - verified April 2012 - Conditions: Carney Complex; Gastrointestinal Stromal Tumor; Paraganglioma; Sarcoma
Interventions: Drug: linsitinib; Genetic: nucleic acid sequencing; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: western blotting; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: positron emission tomography; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Oxaliplatin; Drug: Irinotecan; Drug: 5-FU; Drug: Gemcitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified March 2012 - Conditions: Cerebrovascular Disorders; Deglutition Disorders
Intervention: Behavioral: Establishing Validity and Reliability
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified March 2012 - Condition: Crohn Disease
Interventions: Drug: Infliximab with azathioprine (IIFX + AZA); Drug: Infliximab (IFX alone)
Sponsors: Children's Memorial Health Institute, Poland; Children's Memorial Health Institute, Poland
Active, not recruiting - verified April 2012 - Conditions: Breast Cancer; Cervical Cancer; Colon Cancer; Rectal Cancer; Abnormal Finding in the Breast, Cervix, or Colon and Rectum
Interventions: Behavioral: Patient Navigator matched with subject; Behavioral: Subjects are mailed informational/educational materials
Sponsors: Ohio State University Comprehensive Cancer Center; Electra Paskett; American Cancer Society
Active, not recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Behavioral: Clinic-directed program; Behavioral: Individual Patient-Directed Program
Sponsors: Ohio State University Comprehensive Cancer Center; Electra Paskett; National Cancer Institute (NCI)
Active, not recruiting - verified March 2012 - Conditions: Rectal Cancer; Neoadjuvant Chemotherapy; Short Course Radiotherapy
Interventions: Other: M1 scheme; Other: standard long course chemoradiotherapy
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen; Karolinska University Hospital; Leiden University Medical Center; Uppsala University Hospital
Recruiting - verified March 2012 - Conditions: Enterocutaneous Fistulas; Intra-abdominal Infection
Interventions: Procedure: Autologous platelet-rich fibrin glue (PRFG); Drug: Octreotide
Sponsors: Jinling Hospital, China; Jinling Hospital, China
Recruiting - verified March 2012 - Condition: Esophageal Cancer
Interventions: Behavioral: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log; Behavioral: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012 - Conditions: Colon Cancer; Head and Neck Cancer; Lung Cancer; Lymphoma; Malignant Neoplasm; Melanoma; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Device: merges magnetic resonance imaging with positron emission tomography scanning
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Rectal Neoplasm
Interventions: Procedure: Robotic surgery; Procedure: Laparoscopic surgery
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified May 2012 - Conditions: Pancreatic Cancer; Periampullary Tumor
Interventions: Procedure: Hepaticojejunostomy and gastroenterostomy; Procedure: Stent strategy
Sponsors: Göteborg University; Göteborg University
Recruiting - verified March 2012 - Conditions: Plaque Psoriasis; Crohn's Disease
Interventions: Drug: Adalimumab; Device: Capsule endoscopy
Sponsors: Innovaderm Research Inc.; Innovaderm Research Inc.; Abbott
Not yet recruiting - verified March 2012 - Conditions: Gluten Sensitivity; Celiac Disease
Intervention: Other: Gluten Free Diet
Sponsors: University of Maryland; University of Maryland
Recruiting - verified March 2012 - Condition: Duodenal Diseases
Intervention: Other: Tissue Sampling
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Conditions: PHENYTOIN/SORAFENIB [VA Drug Interaction]; Liver Neoplasms; Carcinoma, Hepatocellular; Digestive System Neoplasms; Neoplasms by Site; Liver Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]; HBV
Interventions: Procedure: Transarterial Chemoembolization (TACE); Other: Sorafenib in combination with TACE
Sponsors: Shandong Cancer Hospital and Institute; Shandong Cancer Hospital and Institute
Not yet recruiting - verified April 2012 - Conditions: Terminal Liver Disease; Ischemia Reperfusion Injury; Graft Dysfunction; Graft Failure; Poor Graft Quality
Interventions: Drug: Tacrolimus; Drug: HTK/Placebo
Sponsors: Ludwig-Maximilians - University of Munich; Ludwig-Maximilians - University of Munich
Recruiting - verified March 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Intervention: Drug: carboplatin and paclitaxel
Sponsors: Korean Gynecologic Oncology Group; Korean Gynecologic Oncology Group
Active, not recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: TroVax®; Biological: Placebo
Sponsors: University College, London; University College, London; Oxford BioMedica; Cancer Research UK
Not yet recruiting - verified March 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Small Bowel Crohn's Disease
Intervention:
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Completed - verified March 2012 - Conditions: Crohn's Disease; Mucosal Inflammation
Interventions: Drug: ADALIMUMAB; Drug: Placebo
Sponsors: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa; Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa; Abbott; INC Research
Not yet recruiting - verified March 2012 - Conditions: Pancreatic Cancer; Rectal Cancer
Intervention: Drug: capecitabine +ganetespib
Sponsors: Emory University; Emory University; Synta Pharmaceuticals Corp.
Not yet recruiting - verified March 2012 - Condition: Colorectal Cancer Screening
Intervention: Other: Patient Navigation
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France; National Cancer Institute, France
Recruiting - verified March 2012 - Condition: Colorectal Cancer, Genetics of
Interventions: Procedure: COLON CAPSULE ENDOSCOPY ADHERENCE; Procedure: OPTICAL COLONOSCOPY ADHERENCE
Sponsors: Hospital Universitario de Canarias; Hospital Universitario de Canarias
Recruiting - verified February 2012 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Not yet recruiting - verified May 2012 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Not yet recruiting - verified May 2012 - Condition: Crohn's Disease
Intervention: Other: Observation study
Sponsors: Kyunghee University Medical Center; Kyunghee University Medical Center; Asan Medical Center; Hanyang university Guri Hospital; Inje University; Seoul National University; Yonsei University; Eisai Korea Inc.; Samsung Medical Center; The Catholic University of Korea; Chung-Ang University
Not yet recruiting - verified March 2012 - Conditions: Non Alcoholic Fatty Liver Disease; Steatohepatitis; Hypertriglyceridemia; Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Intervention: Dietary Supplement: Lovaza
Sponsors: Yale University; Yale University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012 - Conditions: GERD; Esophagitis
Intervention: Procedure: Standard of care endoscopy
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified March 2012 - Conditions: Schistosomiasis; Anemia; Underweight; Stunting; Intestinal Parasites
Intervention:
Sponsors: Biomedical Research Center EPLS; Biomedical Research Center EPLS; Institut Pasteur de Lille; Université de Lille Nord de France; Région Nord-Pas de Calais, France; Center for Infection and Immunity of Lille, France; France: Centre National de la Recherche Scientifique; Institut National de la Santé Et de la Recherche Médicale, France
Completed - verified March 2012 - Condition: Constriction, Pathological
Intervention: Device: Fully coated, removable , self-expanding oesophageal stent
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Rectal Adenocarcinoma
Interventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: 5-FU; Radiation: Radiotherapy
Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University; Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting - verified March 2012 - Condition: Gastrointestinal Hemorrhage
Interventions: Drug: Aspirin (ASA); Drug: Placebo
Sponsors: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology; Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology; Medical Centre of Postgraduate Education, Poland
Not yet recruiting - verified March 2012 - Condition: IBD
Intervention:
Sponsors: Helse Stavanger HF; Helse Stavanger HF
Not yet recruiting - verified March 2012 - Conditions: Portal Hypertension; Cirrhosis
Intervention: Device: Wireless esophageal capsule endoscopy ( PillCam Eso2)
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified March 2012 - Condition: Diarrhea- Irritable Bowel Syndrome
Interventions: Drug: Neu-P11; Drug: Placebo
Sponsors: Ludwig-Maximilians - University of Munich; Ludwig-Maximilians - University of Munich
Enrolling by invitation - verified March 2012 - Condition: Ulcerative Colitis
Interventions: Drug: Infliximab; Drug: Placebo
Sponsors: Xian-Janssen Pharmaceutical Ltd.; Xian-Janssen Pharmaceutical Ltd.
Recruiting - verified May 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab Irinotecan; Drug: Irinotecan Cetuximab
Sponsors: National Engineering Research Center of Antibody Medicine, China; National Engineering Research Center of Antibody Medicine, China; Shanghai Biomabs Pharmaceuticals Co Ltd
Active, not recruiting - verified March 2012 - Conditions: Stage 4 Stomach/Gastric Cancer; Patients and Caregivers
Intervention: Behavioral: bulletin board and teleophone depth interview
Sponsors: Find A Cure Panel; Find A Cure Panel
Recruiting - verified March 2012 - Condition: Gastric Cancer
Interventions: Drug: Peri-operative chemotherapy of ECX; Drug: Peri-operative chemotherapy of XP
Sponsors: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Recruiting - verified March 2012 - Condition: Primary Achalasia
Intervention: Procedure: Peroral endoscopic myotomy
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Polyp; Adenoma
Interventions: Procedure: Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure; Procedure: Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy
Sponsors: Smart Medical Systems Ltd.; Smart Medical Systems Ltd.
Not yet recruiting - verified March 2012 - Conditions: Breast Cancer; Colon Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Advanced Malignant Neoplasm; Colorectal Cancer
Intervention:
Sponsors: Chinese Medical Doctor Association; Chinese Medical Doctor Association
Recruiting - verified March 2012 - Condition: Gastric Adenocarcinoma
Intervention: Drug: S-1 and Oxaliplatin
Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University; Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting - verified March 2012 - Conditions: Malnourishment; Gastrointestinal Tumors
Interventions: Dietary Supplement: Glutamine; Drug: Placebo
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; Fresenius Kabi
Not yet recruiting - verified March 2012 - Condition: Colorectal Adenocarcinoma
Intervention: Drug: Capecitabine
Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University; Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting - verified March 2012 - Conditions: Hepatitis C; Hepatocellular Carcinoma
Intervention: Drug: GS-7977+RBV
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Gastric Adenocarcinoma
Intervention: Drug: Capecitabine, Oxaliplatin, Docetaxel
Sponsors: National Health Research Institutes, Taiwan; National Health Research Institutes, Taiwan; Taipei Veterans General Hospital,Taiwan; Tri-Service General Hospital; Mackay Memorial Hospital; National Cheng-Kung University Hospital
Active, not recruiting - verified March 2012 - Condition: Esophageal Squamous Cell Carcinoma
Interventions: Radiation: docetaxel and cisplatin concurrent chemoradiotherapy; Radiation: docetaxel and cisplatin
Sponsors: The Second People's Hospital of Sichuan; LANG Jin-yi
Active, not recruiting - verified March 2012 - Condition: Cystic Fibrosis Related Bone Disease
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Children's Hospital Boston
Not yet recruiting - verified March 2012 - Conditions: Crohn's Disease; Peritoneal Carcinomatosis With Intestinal Occlusion; Radiation Enteritis; Chronic Diarrhea; Intestinal Lymphomas
Intervention:
Sponsors: Katholieke Universiteit Leuven; Katholieke Universiteit Leuven; Ziekenhuis Netwerk Antwerpen (ZNA); AZ Sint-Lucas Brugge; Universiteit Antwerpen; AZ Sint-Blasius Dendermonde; Imelda Ziekenhuis, Bonheiden; Ziekenhuis Oost Limburg Genk; AZ Sint-Lucas & Volkskliniek, Gent; AZ Damiaan, Oostende; H.-Hartziekenhuis Roeselare-Menen vzw; Universitair Ziekenhuis Brussel; University Hospital, Ghent; Jessa Hospital
Not yet recruiting - verified March 2012 - Condition: Crohn's Disease
Interventions: Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified March 2012 - Condition: Esophageal Cancer
Intervention: Device: wireless pulse oximeter (Wipox)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Liver Cancer
Intervention: Drug: Lenalidomide
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified March 2012 - Condition: Non-alcoholic Fatty Liver Disease
Intervention: Dietary Supplement: Fish Oil
Sponsors: Children's Memorial Health Institute, Poland; Piotr Socha; Medical University of Bialystok; Medical University of Katowice, Poland; Pediatric Municipal Hospital of Rzeszow, Poland
Active, not recruiting - verified March 2012 - Condition: Hypoxic Ischaemic Encephalopathy
Interventions: Drug: xenon gas; Device: Full body cooling
Sponsors: United Bristol Healthcare NHS Trust; United Bristol Healthcare NHS Trust; University of Bristol
Recruiting - verified May 2012 - Condition: Esophageal Cancer
Interventions: Device: submucosal injection needle ; EUS; Device: ordinary endosonography(EUS)
Sponsors: Sun Yat-sen University; Sun Yat-sen University
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Other: Oncology Interactive Navigator; Other: Routine Care
Sponsors: McGill University; McGill University
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Procedure: Surgical resection of recurrent colorectal cancer; Drug: Chemokine-modulatory (CKM) regimen
Sponsors: University of Pittsburgh; University of Pittsburgh
Not yet recruiting - verified March 2012 - Conditions: Colon Cancer; Rectal Cancer; Colonic Diverticulosis
Interventions: Device: Continuous Preperitoneal Analgesia; Device: Continuous Epidural Analgesia
Sponsors: Saint Joseph Mercy Health System; Saint Joseph Mercy Health System
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Intravenous 5 Fluorouracile
Interventions: Genetic: Blood sample for phenotypic and pharmacogenetic analysis.; Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
Sponsors: ICO Paul Papin; ICO Paul Papin
Recruiting - verified March 2012 - Condition: Pancreatic Carcinoma.
Interventions: Drug: Gemzar; Drug: Revlimid
Sponsors: Karolinska University Hospital; Maria Liljefors; Karolinska University Hospital; Karolinska Institutet; Celgene Corporation
Recruiting - verified March 2012 - Condition: Cystic Fibrosis
Intervention: Drug: PUR118
Sponsors: Pulmatrix Inc.; Pulmatrix Inc.; Celerion
Recruiting - verified February 2012 - Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified February 2012 - Condition: Very Low Birth Weight Preterms
Interventions: Drug: Butyrate enemas; Other: Therapeutic abstention
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified February 2012 - Condition: Recto-vaginal Fistula
Intervention: Drug: Adipose-derived stem cells without expanded
Sponsors: Instituto de Investigación Hospital Universitario La Paz; Instituto de Investigación Hospital Universitario La Paz
Recruiting - verified March 2012 - Condition: Colonic Neoplasms
Interventions: Drug: Normal (0.9%) saline; Drug: HalfLytely
Sponsors: Arya, Vijaypal, M.D., P.C.; Arya, Vijaypal, M.D., P.C.
Completed - verified March 2012 - Condition: Enterocutaneous Fistula
Intervention: Drug: Adipose-derived stem cells without expanded
Sponsors: Instituto de Investigación Hospital Universitario La Paz; Instituto de Investigación Hospital Universitario La Paz
Recruiting - verified April 2012 - Condition: Esophageal Cancer
Interventions: Other: chemoradiotherapy; Drug: thalidomide; Other: without thalidomide
Sponsors: Changzhou No.2 People's Hospital; Changzhou No.2 People's Hospital
Recruiting - verified February 2012 - Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: imatinib
Sponsors: Asan Medical Center; Asan Medical Center
Not yet recruiting - verified February 2012 - Condition: Crohn's Disease
Interventions: Dietary Supplement: nutrition treat; Other: surgery
Sponsors: Jinling Hospital, China; Jinling Hospital, China
Recruiting - verified February 2012 - Condition: -kRAS Mutant Stage IV Colorectal Cancer
Intervention: Drug: Vitamin C
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified March 2012 - Conditions: Gastrointestinal Cancer; Lung Cancer
Intervention: Behavioral: Nutrition & physical exercise
Sponsors: Kantonsspital Winterthur KSW; Peter E. Ballmer
Recruiting - verified May 2012 - Condition: Crohn's Disease
Intervention: Biological: Mesenchymal Stem Cells (MSC)
Sponsors: University Hospital of Liege; University Hospital of Liege
Not yet recruiting - verified February 2012 - Conditions: Non-alcoholic Fatty Liver Disease; Morbid Obesity
Intervention: Drug: Ursodeoxycholic Acid (UDCA)
Sponsors: Sahlgrenska University Hospital, Sweden; Sahlgrenska University Hospital, Sweden
Completed - verified March 2012 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Biological: Mycobacterium obuense; Radiation: SBRT
Sponsors: Immodulon Therapeutics Ltd; Immodulon Therapeutics Ltd
Recruiting - verified February 2012 - Condition: Stage IV Pancreatic Cancer
Intervention: Drug: Ascorbic Acid
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Placebo; Drug: Caprelsa (vandetanib)
Sponsors: University of Liverpool; University of Liverpool; AstraZeneca
Recruiting - verified May 2012 - Condition: Crohn's Disease
Interventions: Other: Cx601; Other: Saline solution
Sponsors: Cellerix; Cellerix
Not yet recruiting - verified February 2012 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2012 - Condition: Colon Cancer
Interventions: Other: PEG solution (Fortrans®) and Mentholyptus Drops (Halls®); Other: PEG solution (Fortrans®)
Sponsors: American University of Beirut Medical Center; American University of Beirut Medical Center
Recruiting - verified February 2012 - Condition: Suspected Bilio-pancreatic Disease
Intervention:
Sponsors: Deutsche Klinik fuer Diagnostik; Deutsche Klinik fuer Diagnostik
Completed - verified February 2012 - Conditions: Anemia; Intestinal Helminthiasis; Intestinal Schistosomiasis; Human Immunodeficiency Virus I Infection; Hematologic Diseases; Opportunistic Infections
Interventions: Drug: Praziquantel and Albendazole; Drug: Praziquantel and Albendazole; Drug: Praziquantel and Albendazole
Sponsors: Catholic University of Health and Allied Sciences; Catholic University of Health and Allied Sciences; National Institute for Medical Research, Tanzania; University of Cambridge
Not yet recruiting - verified March 2012 - Conditions: Peritoneal Carcinomatosis; Colorectal Cancer Metastatic
Interventions: Procedure: Cytoreductive surgery; Drug: Hyperthermic intraperitoneal chemotherapy
Sponsors: University of Regensburg; University of Regensburg; Heinrich-Heine University, Duesseldorf
Recruiting - verified March 2012 - Condition: Crohn's Disease
Intervention: Dietary Supplement: VSL#3
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified March 2012 - Conditions: Esophageal Carcinoma; Esophageal Cancer
Intervention: Procedure: Esophagectomy
Sponsors: UMC Utrecht; UMC Utrecht
Recruiting - verified March 2012 - Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Disease
Interventions: Behavioral: Telehealth Behavioral Treatment (TBT); Behavioral: Education Only (EO)
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: Drug: Low dose metformin; Drug: Metformin; Drug: Atorvastatin
Sponsors: University Magna Graecia; Prof Antonino Belfiore
Recruiting - verified February 2012 - Condition: Disorders of Gallbladder, Biliary Tract and Pancreas
Intervention: Drug: propofol
Sponsors: King Chulalongkorn Memorial Hospital; King Chulalongkorn Memorial Hospital
Completed - verified February 2012 - Conditions: Colorectal Neoplasm; Biliary Tract Neoplasm; Liver Neoplasm
Interventions: Dietary Supplement: Whey protein and dietary supplements; Other: prehab exercise
Sponsors: McGill University Health Center; McGill University Health Center
Recruiting - verified February 2012 - Condition: Colon Cancer Liver Metastasis
Intervention: Drug: Bevacizumab
Sponsors: University of Regensburg; University of Regensburg; University of Halle Medical Faculty
Not yet recruiting - verified March 2012 - Condition: Early Gastric Cancer
Intervention: Procedure: Laparoscopic sentinel lymph node biopsy
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified April 2012 - Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Conditions: Obstruction of Biliary Tree; Biliary Tract Cancer; Biliary Tract Neoplasms
Intervention: Device: Radiofrequency ablation catheter (Habib EndoHBP)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Conditions: Breast Cancer; Cancer Survivor; Colorectal Cancer; Lung Cancer; Prostate Cancer; Tobacco Use Disorder
Interventions: Drug: memantine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Squamous Cell Carcinoma of the Esophagus; Stage II Esophageal Cancer; Stage II Gastric Cancer; Stage III Esophageal Cancer; Stage III Gastric Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: oxaliplatin; Drug: fluorouracil; Radiation: radiation therapy; Procedure: conventional surgery; Other: immunohistochemistry staining method; Procedure: positron emission tomography; Procedure: computed tomography; Procedure: laboratory biomarker analysis; Genetic: gene expression analysis; Radiation: fludeoxyglucose F 18
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Active, not recruiting - verified March 2012 - Conditions: Extrahepatic Bile Duct Cancer; Nausea; Vomiting; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: aprepitant; Drug: gemcitabine hydrochloride; Drug: capecitabine; Drug: fluorouracil; Procedure: radiation therapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Procedure: nausea and vomiting therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI); Merck
Active, not recruiting - verified February 2012 - Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib; Drug: sirolimus; Procedure: positron emission tomography; Procedure: computed tomography; Other: pharmacological study; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Conditions: Reflux Esophagitis (RE); Non-erosive Reflux Disease (NERD); Functional Heartburn (FH)
Intervention:
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Completed - verified February 2012 - Conditions: Colitis, Ulcerative; Inflammatory Bowel Diseases
Interventions: Drug: CGMP protein; Drug: Maximal oral 5ASA
Sponsors: University of Aarhus; University of Aarhus; Arla Foods
Recruiting - verified March 2012 - Conditions: Appendicitis; Child
Interventions: Procedure: Appendectomy; Drug: Conservative, non-surgical treatment
Sponsors: Karolinska University Hospital; Karolinska University Hospital
Recruiting - verified April 2012 - Conditions: Esophageal Deviation; Atrial Fibrillation; Ablation
Intervention: Procedure: esophageal deviation
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Boston Scientific Corporation
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Colorectal Adenomas
Interventions: Procedure: FlexSig; Procedure: iFOBT
Sponsors: Norwegian Department of Health and Social Affairs; Norwegian Department of Health and Social Affairs
Not yet recruiting - verified February 2012 - Conditions: Liver Cancer; Portal Vein Thrombosis
Intervention: Device: TheraSphere
Sponsors: Emory University; Emory University
Recruiting - verified April 2012 - Condition: Advanced Gastric Carcinoma
Interventions: Drug: Oxaliplatin capecitabine; Drug: Oxaliplatin S-1; Drug: Oxaliplatin S-1
Sponsors: Peking University; Peking University; Sanofi-Aventis; Taiho Pharmaceutical Co., Ltd.
Not yet recruiting - verified February 2012 - Condition: Nonpolypoid Colorectal Neoplasms(NP-CRN)
Intervention:
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Completed - verified February 2012 - Conditions: Colon Neoplasm; Pain
Interventions: Procedure: air insufflation; Procedure: water immersion; Procedure: water exchange
Sponsors: Dalin Tzu Chi General Hospital; Dalin Tzu Chi General Hospital
Not yet recruiting - verified February 2012 - Conditions: Carcinoma; Liver Diseases; Hepatocellular Carcinoma
Intervention: Drug: S-1 combined with Leucovorin
Sponsors: Second Military Medical University; Second Military Medical University
Recruiting - verified February 2012 - Condition: Liver Disease
Interventions: Biological: Lyophilized Plasma; Biological: Licensed Plasma
Sponsors: HemCon Medical Technologies, Inc; HemCon Medical Technologies, Inc
Not yet recruiting - verified March 2012 - Conditions: Cardiac Rhythm Disorders; Urological and Digestive Disorders
Intervention:
Sponsors: Medtronic; Medtronic
Recruiting - verified January 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: fluorouracil/irinotecan/levo-folinic acid/bevacizumab
Sponsors: University of Rome Tor Vergata; University of Rome Tor Vergata
Not yet recruiting - verified February 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab, oxaliplatin and 5FU combination; Drug: Bevacizumab, oxaliplatin and raltitrexed combination
Sponsors: Centre Val d'Aurelle - Paul Lamarque; Centre Val d'Aurelle - Paul Lamarque
Recruiting - verified February 2012 - Condition: Colorectal Cancer Screening
Intervention: Behavioral: surveys
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Albert Einstein College of Medicine of Yeshiva University; HHC, Gun HIll and Tremont; NYC RING, Director; Virginia Commonwealth University
Not yet recruiting - verified February 2012 - Conditions: Hepatitis C, Chronic; Non-Alcoholic Fatty Liver Disease
Intervention: Device: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Sponsors: HepQuant, LLC; HepQuant, LLC
Recruiting - verified April 2012 - Condition: Inflammatory Bowel Disease
Interventions: Biological: ENGERIX-B (HBV Vaccine); Biological: Sci-B-Vac
Sponsors: Soroka University Medical Center; Soroka University Medical Center
Not yet recruiting - verified April 2012 - Conditions: Colonic Polyps; Cancer Colon; Inflammatory Bowel Disease
Interventions: Drug: polyethylene glycol (PEG); Drug: PEG low volume with bisacodyl
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Completed - verified March 2010 - Condition: Functional Gastrointestinal Disorders
Interventions: Drug: Amoxicillin; Other: Placebo
Sponsors: Nationwide Children's Hospital; Nationwide Children's Hospital
Recruiting - verified February 2012 - Conditions: Colorectal Cancer; Colon Cancer; Prostate Cancer
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Completed - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: Apatinib; Drug: apatinib
Sponsors: Jiangsu HengRui Medicine Co., Ltd.; Jiangsu HengRui Medicine Co., Ltd.; Fudan University
Recruiting - verified February 2012 - Conditions: Pancreatitis, Chronic; Abdominal Pain; Chronic Pain
Interventions: Drug: Tetrahydrocannabinol; Drug: Placebo
Sponsors: Radboud University; Radboud University; European Union
Not yet recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Severe Combined Immunodeficiency; Severe Congenital Neutropenia; Shwachman-Diamond Syndrome; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia; Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Stroke
Intervention:
Sponsors: Rhode Island Hospital; Rhode Island Hospital
Recruiting - verified March 2012 - Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Childhood Alveolar Soft-part Sarcoma; Childhood Angiosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Childhood Epithelioid Hemangioendothelioma; Childhood Epithelioid Sarcoma; Childhood Fibrosarcoma; Childhood Leiomyosarcoma; Childhood Liposarcoma; Childhood Malignant Hemangiopericytoma; Childhood Malignant Mesenchymoma; Childhood Neurofibrosarcoma; Childhood Synovial Sarcoma; Dermatofibrosarcoma Protuberans; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: gemcitabine hydrochloride; Drug: pazopanib hydrochloride; Other: placebo; Other: laboratory biomarker analysis
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Stomach Neoplasms
Interventions: Drug: Oxaliplatin; Drug: s1
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified February 2012 - Condition: Diverticular Disease of the Colon
Interventions: Drug: Mesalazine plus Lactobacillus casei; Drug: Mesalazine placebo plus Lactobacillus casei placebo; Drug: Mesalazine 800 mg; Drug: Lactobacillus casei
Sponsors: Hospital Cristo Re; Hospital Cristo Re
Completed - verified February 2012 - Condition: Colorectal Cancer
Interventions: Drug: Endostatins (Endostar); Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences; Simcere Pharmaceutical Co., Ltd
Recruiting - verified February 2012 - Condition: Hepatic Impairment
Intervention: Drug: AGO178
Sponsors: Novartis; Novartis Pharmaceuticals; Servier
Completed - verified February 2012 - Condition: Biliary Tract Cancer
Interventions: Drug: capecitabine and mitomycin; Drug: Capecitabine
Sponsors: IRCCS San Raffaele; IRCCS San Raffaele; Regione Lombardia
Recruiting - verified February 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: Bevacizumab plus alternating Xelox/Xeliri
Sponsors: Helsinki University Central Hospital; Pia Osterlund
Recruiting - verified February 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Other: Biomarker sampling
Sponsors: Helsinki University Central Hospital; Pia Osterlund
Recruiting - verified February 2012 - Condition: Other Condition That May be a Focus of Clinical Attention
Intervention: Biological: Vaccination against hepatitis A
Sponsors: Federal University of São Paulo; Federal University of São Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo; AFIP: Associação Fundo de Incentivo à Pesquisa
Not yet recruiting - verified February 2012 - Conditions: Gastric Cancer; Type 2 Diabetes
Intervention: Procedure: Stomach-small intestine reconstruction
Sponsors: Xiamen University; feng Zheng
Recruiting - verified February 2012 - Condition: Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES
Intervention: Procedure: Per-Oral Endoscopic Myotomy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified October 2010 - Conditions: Achalasia; Hypertensive LES
Intervention: Procedure: Per Oral Endoscopic Myotomy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified February 2012 - Condition: Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Achalasia
Intervention: Procedure: Per Oral Endoscopic Myotomy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2012 - Conditions: Mucinous Cystic Tumor With Moderate Dysplasia; Mucinous Cystadenoma of Pancreas; Mucinous Cystadenocarcinoma of Pancreas; Benign Neoplasm of Pancreas
Intervention: Drug: Ethanol and Paclitaxel Injection
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; University of Western Ontario, Canada
Not yet recruiting - verified February 2012 - Condition: Metastatic Gastric Cancer
Intervention: Drug: Panobinostat (LBH589)
Sponsors: Technische Universität München; Technische Universität München; Novartis
Recruiting - verified May 2011 - Condition: Crohn´s Disease
Interventions: Drug: Metronidazol; Drug: Metronidazol; Drug: Azatioprina; Drug: Adalimumab
Sponsors: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa; Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa; Effice Servicios Para la Investigacion S.L.
Active, not recruiting - verified March 2012 - Condition: Pancreatic Disease
Interventions: Procedure: Total parenteral nutrition; Procedure: Enteral nutrition
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified April 2012 - Condition: Inflammatory Bowel Diseases
Intervention:
Sponsors: Oslo University Hospital; Oslo University Hospital
Completed - verified January 2012 - Condition: Esophageal Cancer
Interventions: Drug: Chemotherapy; Radiation: Radiotherapy
Sponsors: Centre Oscar Lambret; Centre Oscar Lambret
Completed - verified February 2012 - Conditions: Acute Appendicitis; Perforated Gastroduodenal Ulcer; Small Bowel Obstruction
Interventions: Drug: Metronidazole, Cefuroxime; Drug: Amoxicillin (+ clavulanic acid) and Fluconazole; Drug: Placebo; Drug: Placebo
Sponsors: The Faculty Hospital Na Bulovce; The Faculty Hospital Na Bulovce
Completed - verified January 2012 - Conditions: Colorectal Cancer; Colorectal Liver Metastasis; Liver Surgery; Exercise Intervention
Intervention: Behavioral: Exercise Intervention
Sponsors: Aintree University Hospitals NHS Foundation Trust; Aintree University Hospitals NHS Foundation Trust
Recruiting - verified February 2012 - Conditions: Breast Cancer; Colorectal Cancer; Lymphoma; Prostate Cancer; Testicle Cancer
Intervention: Other: Stressmanagement
Sponsors: Haukeland University Hospital; Haukeland University Hospital; University of Bergen; Uppsala University; University of Agder
Recruiting - verified January 2012 - Conditions: Melanoma; Merkel Cell Carcinoma; Squamous Cell Carcinoma; Penile Carcinoma; Urethral Carcinoma; Extramammary Paget's Disease; Scrotal Carcinoma; Anal Cancer; Vulvar Cancer; Skin Cancer; Lymphadenopathy
Interventions: Procedure: Videoscopic procedure; Procedure: Open, traditional approach
Sponsors: Emory University; Emory University
Recruiting - verified February 2012 - Condition: Colon Cancer Liver Metastasis
Intervention: Procedure: Contrast-enhanced intraoperative ultrasound
Sponsors: University of Milan; University of Milan
Completed - verified January 2012 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: Cetuximab; Drug: 5-fluorouracil; Drug: leucovorin
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Not yet recruiting - verified January 2012 - Conditions: Cholangiocarcinoma; Pancreatic Cancer; Bile Duct Cancer; Biliary Stricture; Biliary Obstruction; Stent Obstruction; Proximal Duct Stricture; Distal Duct Stricture; Ampullary Cancer; Biliary Sphincter Stenosis; Impacted Stones; Chronic Pancreatitis; Peri-ampullary Diverticula; Altered Anatomy
Intervention: Procedure: Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified January 2012 - Conditions: Colorectal Cancer; Steatohepatitis
Intervention: Drug: Metformin/Placebo
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Merck Gesellschaft mbH, Austria
Recruiting - verified April 2012 - Condition: Colon Cancer
Intervention: Drug: PDT with 5-ALA radiosensitization
Sponsors: Holcombe, Randall F., M.D.; Holcombe, Randall F., M.D.; University of California, Irvine; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Gallbaldder Cancer; Gallstones
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); Pontificia Universidad Catolica de Chile
Recruiting - verified October 2011 - Conditions: Metastatic Pancreatic Cancer; ERCC1
Intervention: Drug: gemcitabine and oxaliplatin
Sponsors: University of Hawaii; University of Hawaii
Recruiting - verified January 2012 - Condition: Hepatocellular Carcinoma
Intervention:
Sponsors: Ain Shams University; Ain Shams University
Recruiting - verified January 2012 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsConditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Esophageal Cancer; Gastric Cancer
Intervention: Drug: Afatinib (BIBW 2992)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Device: PillCam Colon Capsule Endoscopy (Given® Diagnostic System)
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified February 2012 - Condition: Colorectal Neoplasms
Intervention:
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Completed - verified January 2012 - Condition: Rectal Cancer
Intervention: Device: MRI,PET-CT and CT-Perfusion studies
Sponsors: London Health Sciences Centre; London Health Sciences Centre
Not yet recruiting - verified January 2012 - Conditions: Pulmonary Infections; Pseudomonas Aeruginosa in Cystic Fibrosis
Intervention: Drug: Tobramycin inhalation powder
Sponsors: Novartis; Novartis
Recruiting - verified January 2012 - Condition: Colorectal Neoplasms
Intervention:
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Completed - verified January 2012 - Conditions: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis
Interventions: Device: Endoscopy (EPK-i, Pentax, Tokyo, Japan); Device: Endomicroscopy (iCLE, Pentax, Tokyo, Japan); Device: Endoscopy (EPK-i, Pentax, Tokyo, Japan); Device: Endomicroscopy (iCLE, Pentax, Tokyo, Japan)
Sponsors: University of Erlangen-Nürnberg Medical School; University of Erlangen-Nürnberg Medical School
Not yet recruiting - verified January 2012 - Conditions: Hemolytic Uremic Syndrome; Hemorrhagic Colitis; Intestinal Infectious Disease; Intestinal Infection Due to E. Coli
Intervention: Drug: polyethylene glycol solution for daily bowel lavage.
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Universitätsklinikum Hamburg-Eppendorf
Completed - verified March 2012 - Conditions: Metastatic Pancreatic Cancer; Pancreatic Cancer
Intervention: Drug: Folfirinox
Sponsors: Yale University; Yale University
Recruiting - verified January 2012 - Condition: Ulcerative Colitis
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Diabetes Mellitus; Prediabetes; Morbid Obesity; Gastric Cancer; Colorectal Cancer
Intervention: Other: Interview, questionnaire, updated biochemical tests
Sponsors: University of Sao Paulo; University of Sao Paulo
Completed - verified January 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: CPT-11
Sponsors: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Behavioral: Stage 1; Behavioral: Stage 2
Sponsors: Philadelphia Veterans Affairs Medical Center; Philadelphia Veterans Affairs Medical Center; VA Pittsburgh Healthcare System
Enrolling by invitation - verified April 2012 - Condition: Hepatic Impairment
Interventions: Drug: Cohort 1; Drug: Cohort 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Conditions: Crohn's Disease; Fatigue
Interventions: Dietary Supplement: L-carnitine; Other: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified January 2012 - Condition: Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: Drug: delayed release cysteamine bitartrate; Other: DR cysteamine bitartrate placebo
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Intervention: Drug: Gemcitabine with escalating ascorbic acid
Sponsors: University of Iowa; University of Iowa; Susan L Bader Foundation of Hope; The Holden Comprehensive Cancer Center; The National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Behavioral: Colorectal Web
Sponsors: University of Michigan Health System; University of Michigan Health System
Not yet recruiting - verified March 2012 - Condition: Gastric Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012 - Condition: Malignant Tumor of Extrahepatic Bile Duct
Interventions: Device: WInged perimeter biliary stent insertion (Viaduct); Device: traditional polyethylene stent insertion (Cotton Huibregtse)
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified January 2012 - Condition: Functional Dyspepsia
Interventions: Drug: Rabeprazole and Amoxicillin; Drug: Amoxicillin and Rabeprazole
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Completed - verified January 2012 - Condition: Pancreatic Cancer
Intervention: Drug: GRASPA
Sponsors: ERYtech Pharma; ERYtech Pharma
Completed - verified January 2012 - Condition: Hepatocellular Carcinoma
Intervention: Procedure: Transarterial chemoembolisation using cisplatin-lipiodol mixture
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2012 - Condition: Non Alcoholic Fatty Liver Disease
Interventions: Dietary Supplement: RGMA001; Dietary Supplement: Sugar Pill
Sponsors: Biovil Research Group, LLC; Biovil Research Group, LLC
Enrolling by invitation - verified January 2012 - Condition: Esophageal Cancer
Interventions: Radiation: Proton Beam Therapy (PBT); Radiation: Intensity Modulated Radiation Therapy (IMRT); Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Secondary Malignant Neoplasm of Liver; Colorectal Neoplasms
Interventions: Procedure: Open liver resection; Procedure: Laparoscopic liver resection
Sponsors: Oslo University Hospital; Oslo University Hospital; Helse Sor-Ost
Recruiting - verified February 2012 - Conditions: Colorectal Cancer Screening; Shared Decision Making
Interventions: Behavioral: Shared Decision Making for Colorectal Cancer Screening; Behavioral: Control
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; Allina Health System; Blue Cross Blue Shield
Not yet recruiting - verified March 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: FOLFOX + bevacizumab; Dietary Supplement: Vitamin D; Dietary Supplement: Vitamin D
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified April 2012 - Condition: Advanced or Metastatic Gastric Cancer
Interventions: Drug: apatinib; Drug: placebo
Sponsors: Jiangsu HengRui Medicine Co., Ltd.; Jiangsu HengRui Medicine Co., Ltd.; Fudan University; No.81 Hospital of the PLA
Recruiting - verified January 2012 - Condition: Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Conditions: Colorectal Cancer; Colorectal Adenomas; Inflammatory Bowel Disease
Intervention: Procedure: Fujinon EC-450BI5 double-balloon colonoscope
Sponsors: Sorlandet Hospital HF; Sorlandet Hospital HF; South-Eastern Norway Regional Health Authority; Fujifilm Europa
Recruiting - verified April 2012 - Conditions: Constipation; Hirschsprung Disease
Intervention: Procedure: Endoscopic mucosal resection (EMR)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified January 2012 - Condition: Psychological Stress
Intervention: Behavioral: Telephone intervention
Sponsors: Hospital Authority, Hong Kong; Hospital Authority, Hong Kong
Recruiting - verified January 2012 - Conditions: Gastric Tumor; Helicobacter Pylori; Endoscopic Resection; Metachronous Neoplasms
Intervention: Drug: eradication treatment of Helicobacter pylori infection
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Completed - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Radiation: Radiotherapy; Drug: Tarceva; Drug: Oxaliplatin
Sponsors: Institut Català d'Oncologia; Institut Català d'Oncologia
Recruiting - verified February 2012 - Condition: Crohn's Disease
Interventions: Drug: D9421-C capsule 3 mg; Drug: Mesalazine tablets
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Condition: Colorectal Polyps
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic; Bankhead-Coley
Recruiting - verified January 2012 - Conditions: Meconium Ileus; Very Low Birth Weight Infant
Interventions: Drug: Gastrografin; Drug: Sterile water
Sponsors: Medical University of Vienna; Nadja Haiden
Completed - verified January 2012 - Conditions: Gastrinoma; Glucagonoma; Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Recurrent Pancreatic Cancer; Somatostatinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: temozolomide; Biological: bevacizumab
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Conditions: Breast Cancer; Colon Cancer; Gastric Cancer; Lung Cancer
Interventions: Behavioral: Tailored health partnership program; Behavioral: Usual care and health education workshop
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea; Samsung Medical Center; Seoul National University Hospital; Korea University Anam Hospital; Asan Medical Center; Ajou University School of Medicine; Kyunghee University Medical Center
Recruiting - verified February 2012 - Condition: Pancreatic Tumors
Intervention: Drug: Definity Contrast
Sponsors: University of Vermont; University of Vermont
Not yet recruiting - verified February 2012 - Condition: Gastric Cancer
Interventions: Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin; Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin; Drug: Oxaliplatin; Capecitabine
Sponsors: Hebei Medical University; Hebei Medical University
Recruiting - verified March 2012 - Condition: Gastric Cancer
Interventions: Drug: DOCETAXEL (XRP6976); Drug: OXALIPLATIN (SR96669); Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + CDHP (Gemeracil) + Oxo (Oteracil)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Crohn's Disease
Intervention: Drug: PROCHYMAL (remestemcel-L)
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Enrolling by invitation - verified January 2012 - Condition: Rotavirus Gastroenteritis
Intervention:
Sponsors: Society for Applied Studies; Society for Applied Studies; National Institute of Immunology, New Delhi; Ministry of Science and Technology, India
Completed - verified January 2012 - Conditions: Colorectal Cancer Metastatic; Liver Metastases; KRAS Wild Type Colorectal Cancer
Intervention: Drug: 5-FU, Folinic Acid, Oxaliplatin, Bevacizumab, Panitumumab
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; Amgen; Roche Pharma AG
Not yet recruiting - verified January 2012 - Conditions: Liver Neoplasms; Colonic Neoplasms; Metastatic Cancer to Liver
Intervention: Radiation: Stereotactic Radiosurgery using the CyberKnife System.
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified February 2012 - Condition: Stomach Neoplasms
Intervention:
Sponsors: Shanghai Jiao Tong University School of Medicine; Xiaobo Li
Completed - verified January 2012 - Condition: Gastro-oesophageal Reflux Disease
Intervention:
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified January 2012 - Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012 - Condition: Rectal Cancer
Interventions: Other: Chemoradiation Therapy; Drug: Cyclophosphamide; Biological: L-BLP25; Other: Chemoradiation Therapy; Biological: L-BLP25; Other: Chemoradiation Therapy
Sponsors: Merck KGaA; Merck KGaA
Recruiting - verified January 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Metastatic Pancreatic Cancer
Intervention: Drug: TL-118
Sponsors: Tiltan Pharma Ltd.; Tiltan Pharma Ltd.
Recruiting - verified February 2012 - Conditions: Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: 90Y-hPAM4
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified May 2012 - Conditions: Pancreatic Cancer; Hypoxia
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Cancer Society
Recruiting - verified March 2012 - Conditions: Alcoholism,; Alcoholic Liver Disease
Interventions: Drug: Metadoxine; Drug: Placebo
Sponsors: Brown University; Brown University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified January 2012 - Condition: Gastroesophageal Reflux Disease
Interventions: Other: symptom questionaire; Procedure: pH monitoring; Procedure: Tri-modal imaging endoscopy; Drug: rabeprazole
Sponsors: Chinese PLA General Hospital; Chinese PLA General Hospital
Recruiting - verified February 2012 - Conditions: Dysphagia; Aspiration; Quality of Life
Intervention: Procedure: Injection laryngoplasty
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified January 2012 - Condition: Colon Cancer
Interventions: Biological: FANG Vaccine; Drug: Placebo
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012 - Conditions: Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Drug: LY2495655; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Suspended - verified May 2012 - Conditions: Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach; Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
Intervention:
Sponsors: Guangxi Medical University; Guangxi Medical University
Completed - verified January 2012 - Conditions: Advanced Solid Tumors; Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: BKM120; Drug: mFOLFOX6
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Not yet recruiting - verified January 2012 - Condition: Colon Cancer
Intervention: Other: Colorectal cancer screening pamphlet
Sponsors: University of Oklahoma; University of Oklahoma
Completed - verified January 2012 - Condition: Irritable Bowel Syndrome Without Diarrhea
Interventions: Drug: Probiotics (Medirac); Drug: Probiotics (Medirac); Drug: Probiotics (Medirac); Drug: Probiotics (Medirac); Drug: Probiotics (Medirac) placebo/mosapride placebo
Sponsors: Hanmi Pharmaceutical Company Limited; Hanmi Pharmaceutical Company Limited
Recruiting - verified December 2011 - Conditions: Gastric Adenocarcinoma With Peritoneal Carcinomatosis; Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis; Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
Interventions: Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel; Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel
Sponsors: AIO-Studien-gGmbH; AIO-Studien-gGmbH; Fresenius Biotech GmbH
Recruiting - verified January 2012 - Conditions: Advanced Adenocarcinoma; Metastatic Adenocarcinoma
Interventions: Drug: Hydroxychloroquine (HCQ); Drug: Gemcitabine
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Conditions: Colorectal Liver Metastasis; Contrast Enhances Intraoperative Ultrasound; Imaging for Liver Cancer; Imaging for Liver Metastasis
Interventions: Procedure: Liver Surgery; Device: Contrast Enhanced Ultrasound; Radiation: CT Scan (standard); Radiation: Primovist MRI (3 Tesla)
Sponsors: Asklepios Kliniken Hamburg GmbH; Asklepios Kliniken Hamburg GmbH
Recruiting - verified January 2012 - Condition: Crohn's Disease
Intervention: Drug: 23-valent polysaccharide pneumococcal vaccine
Sponsors: Kyunghee University Medical Center; Kyunghee University Medical Center; Yonsei University; Seoul National University Hospital; Asan Medical Center; Soonchunhyang University Hospital; Ewha Womans University; Kosin University Gospel Hospital; Chung-Ang University; Inje University; The Catholic University of Korea; Keimyung University Dongsan Hospital; Korea University; Wonkwang University; Severance Hospital; Konkuk University Hospital
Recruiting - verified January 2012 - Condition: Pancreatic Cancer
Intervention: Drug: Tarceva(Erlotinib), Gemcitabine, Oxaliplatin
Sponsors: Soonchunhyang University Hospital; Soonchunhyang University Hospital
Recruiting - verified January 2012 - Condition: Recurrent Rectal Cancer
Intervention: Radiation: Carbon Ion Radiotherapy
Sponsors: University Hospital Heidelberg; University Hospital Heidelberg
Not yet recruiting - verified February 2012 - Conditions: Intestinal Tuberculosis; Pulmonary Tuberculosis; Crohn's Disease
Intervention:
Sponsors: Lovisenberg Diakonale Hospital; Lovisenberg Diakonale Hospital; Helse Sor-Ost; The Unger-Vetlesen Medical Fund, Jersey, C.I; Odd Fellow Medical Fund, Norway
Recruiting - verified December 2011 - Conditions: Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; Drug: sirolimus; Other: laboratory biomarker analysis; Biological: sargramostim
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Early Gastric Cancer
Intervention: Device: Robot assisted distal gastrectomy (DaVinci)
Sponsors: Shizuoka Cancer Center; Shizuoka Cancer Center
Recruiting - verified January 2012 - Conditions: Asthma; Gastroesophageal Reflux Disease
Intervention:
Sponsors: Children's Center for Digestive Health Care; Children's Center for Digestive Health Care; Takeda Pharmaceuticals North America, Inc.
Active, not recruiting - verified February 2012 - Conditions: Ulcerative Colitis; Crohn's Colitis
Interventions: Procedure: Colonoscopy with Indigo-Carmine chromoendoscopy; Procedure: Conventional white-light colonoscopy
Sponsors: Karolinska University Hospital; Karolinska University Hospital
Recruiting - verified January 2012 - Conditions: Chronic Diarrhoea; Lymphocytic Colitis; Collagenous Colitis
Intervention: Procedure: Colonoscopy with Indigo-Carmine Chromoendoscopy
Sponsors: Karolinska University Hospital; Karolinska University Hospital
Recruiting - verified January 2012 - Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Hepatocellular Carcinoma; Obstructive Jaundice
Intervention: Drug: Photofrin
Sponsors: Samsung Medical Center; Samsung Medical Center
Completed - verified January 2012 - Condition: Alcoholic Liver Disease
Intervention: Drug: LACTOWELL
Sponsors: Chuncheon Sacred Heart Hospital; Chuncheon Sacred Heart Hospital
Recruiting - verified December 2011 - Condition: Dysphagia
Intervention: Device: Esophageal calibration tube
Sponsors: Antalya Training and Research Hospital; Antalya Training and Research Hospital
Completed - verified December 2011 - Conditions: Lung Cancer; Breast Cancer; Colorectal Cancer; Cholangiocarcinoma; Solid Tumors
Intervention: Drug: BKM120
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Barrett's Esophagus
Intervention:
Sponsors: NinePoint Medical; NinePoint Medical
Recruiting - verified April 2012 - Condition: Gastro Esophageal Reflux Disease
Interventions: Device: Bravo® pH Monitoring System; Device: Bravo® pH Monitoring System
Sponsors: Given Imaging Ltd.; Given Imaging Ltd.
Not yet recruiting - verified January 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: docetaxel; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Advanced Gastric Cancer
Interventions: Drug: Pazopanib; Drug: 5-FU, Oxaliplatin, Leukovorin (FLO)
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany
Recruiting - verified January 2012 - Condition: Pancreas Cancer
Interventions: Drug: Neoadjuvant chemotherapy; Procedure: surgery and Adjuvant chemotherapy
Sponsors: Institut Paoli-Calmettes; Institut Paoli-Calmettes
Recruiting - verified January 2012 - Conditions: Gastrointestinal Cancer; Nausea Post Chemotherapy
Intervention: Drug: fosaprepitant dimeglumine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Condition: Esophageal Squamous Cell Carcinoma.
Intervention:
Sponsors: Samsung Medical Center; Samsung Medical Center
Not yet recruiting - verified December 2011 - Condition: Rectal Cancer
Interventions: Drug: Capecitabine; Drug: 5-FU
Sponsors: University Hospital Mannheim; University Hospital Mannheim
Completed - verified December 2011 - Condition: Colorectal Cancer
Intervention: Drug: PF-0332991, 5-FU, oxaliplatin
Sponsors: Georgetown University; Georgetown University; Pfizer
Recruiting - verified December 2011 - Conditions: Kidney Cancer; Liver Cancer
Interventions: Drug: hypoxia-activated prodrug TH-302; Drug: sorafenib tosylate; Genetic: protein analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011 - Conditions: Stomach Neoplasms; Metaplasia
Intervention: Procedure: Acetic acid chromoendoscopy
Sponsors: Konyang University Hospital; Konyang University Hospital
Completed - verified April 2012 - Condition: Irritable Bowel Syndrome With Diarrhea
Intervention:
Sponsors: Katholieke Universiteit Leuven; Katholieke Universiteit Leuven
Recruiting - verified December 2011 - Condition: Cystic Fibrosis
Intervention: Dietary Supplement: Ensure plus
Sponsors: University of Arkansas; University of Arkansas; Arkansas Children's Hospital Research Institute
Active, not recruiting - verified December 2011 - Conditions: Ulcerative Colitis; Crohn's Disease; Inflammatory Bowel Disease
Interventions: Dietary Supplement: AndoSan; Dietary Supplement: Sugar Extract
Sponsors: Oslo University Hospital; Oslo University Hospital; ImmunoPharma
Recruiting - verified December 2011 - Conditions: Colon Cancer; Lynch Syndrome
Intervention: Procedure: MSI screening test
Sponsors: Kaiser Permanente; Kaiser Permanente; Case Western Reserve University; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute
Enrolling by invitation - verified April 2012 - Conditions: Irritable Bowel Syndrome; Non Cardiac Chest Pain; Cyclical Vomiting Syndrome; Functional Dyspepsia; Gastroparesis; Ulcerative Colitis; Vulvodynia; Crohn's Disease
Intervention:
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Conditions: Fallopian Tube Cancer; Fatigue; Neuropathy; Neurotoxicity; Ovarian Cancer; Pain; Primary Peritoneal Cavity Cancer
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Conditions: Colonic Diverticula; Diverticulitis
Intervention:
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center
Not yet recruiting - verified January 2012 - Condition: Breast Cancer, Colorectal Cancer
Interventions: Drug: capecitabine RTD; Drug: capecitabine [Xeloda]; Drug: capecitabine [Xeloda]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Drug: Panitumumab and bortezomib
Sponsors: Georgetown University; Georgetown University; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Rectal Adenocarcinoma
Intervention: Procedure: MR saline peritoneography
Sponsors: Cliniques universitaires Saint-Luc- Université Catholique de Louvain; Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Enrolling by invitation - verified December 2011 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012 - Condition: Gastroesophageal Reflux
Interventions: Drug: Zegerid; Drug: Losec
Sponsors: Norgine; Norgine
Completed - verified November 2011 - Conditions: Depression; Hepatitis c
Intervention:
Sponsors: Centro Hospitalar Lisboa Norte; Centro Hospitalar Lisboa Norte
Not yet recruiting - verified December 2011 - Conditions: Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Malignant Tumor of Peritoneum; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
Interventions: Radiation: stereotactic body radiation therapy; Procedure: positron emission tomography; Procedure: computed tomography; Other: questionnaire administration; Radiation: fludeoxyglucose F 18
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012 - Conditions: Malignant Rectal Neoplasm; Recurrent Tumor
Intervention: Radiation: intraoperative radiotherapy
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia
Completed - verified December 2011 - Condition: Pancreatic Cancer
Intervention: Radiation: MeIQx
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified January 2012 - Condition: Colitis, Ulcerative
Interventions: Drug: Kappaproct; Drug: Placebo
Sponsors: InDex Pharmaceuticals; InDex Pharmaceuticals
Recruiting - verified May 2012 - Condition: Colorectal Neoplasms
Interventions: Behavioral: CRCS patient decision aid (PtDA) video; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011 - Condition: Opioid Induced Swallowing Disorders
Interventions: Drug: Remifentanil; Drug: Placebo; Drug: Technetium; Device: Dynamometer (Jamar)
Sponsors: University Hospital Orebro; University Hospital Orebro
Recruiting - verified January 2012 - Condition: Gastric Cancer
Interventions: Procedure: Roux-en-Y pouch reconstruction (RYP); Procedure: conventional Roux-en-Y reconstruction (RYC)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; McMaster University
Recruiting - verified December 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001; Drug: pegylated liposomal doxorubicin hydrochloride; Genetic: RNA analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Other: Six and three time schedule; Other: Four and two time schedule
Sponsors: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology; Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology; The National Centre for Research and Development, Poland
Completed - verified January 2012 - Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Veliparib and 5-FU and Oxaliplatin and Leucovorin
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified December 2011 - Condition: Pediatric Inflammatory Bowel Disease
Intervention:
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Not yet recruiting - verified December 2011 - Conditions: Carcinoma, Hepatocellular; Liver Dysfunction
Interventions: Drug: Gd-EOB-DTPA; Drug: Gd-EOB-DTPA; Device: MRI; Device: MRI
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Bayer; Seoul St. Mary's Hospital; Asan Medical Center; Chonnam National University Hospital
Recruiting - verified December 2011 - Conditions: Colonic Cancer; Metastasis
Interventions: Drug: Oral complex C3 curcumin + chemotherapy; Drug: Chemotherapy only
Sponsors: University of Leicester; University of Leicester
Not yet recruiting - verified December 2011 - Condition: Stage IV Gastric Cancer With Metastasis
Interventions: Drug: Trastuzumab; Drug: Capecitabine; Drug: Oxaliplatin
Sponsors: Fundación para el Progreso de la Oncología en Cantabria; Fundación para el Progreso de la Oncología en Cantabria
Recruiting - verified April 2012 - Condition: Crohn Disease
Interventions: Dietary Supplement: Oligofructose enriched inulin; Dietary Supplement: Maltodextrin
Sponsors: Katholieke Universiteit Leuven; Katholieke Universiteit Leuven
Completed - verified December 2011 - Condition: Gastric Cancer
Intervention: Drug: cabazitaxel XRP6258
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Drug-Eluting Beads with Doxorubicin; Drug: Lipiodol ethanol mixture
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Non Alcoholic Fatty Liver Disease; Type 2 Diabetes; Liver Cirrhosis
Interventions: Other: OGTT; Other: IIGI
Sponsors: University Hospital, Gentofte, Copenhagen; University Hospital, Gentofte, Copenhagen
Recruiting - verified December 2011 - Condition: Upper Gastrointestinal Symptoms
Interventions: Procedure: endoscopy after short fasting; Procedure: conventional fasting
Sponsors: Universidade de Passo Fundo; Universidade de Passo Fundo; Federal University of Rio Grande do Sul
Completed - verified December 2011 - Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Intervention: Drug: LDE225+gemcitabine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Advanced Metastatic Gastric Cancer; Recurrent Gastric Cancer
Intervention: Drug: Paclitaxel
Sponsors: Hanmi Pharmaceutical Company Limited; Hanmi Pharmaceutical Company Limited
Recruiting - verified December 2011 - Conditions: Liver Disease; Pulmonary Embolism; Thrombophilia; Death
Interventions: Procedure: Liver resection; Radiation: Computed Tomography
Sponsors: Beaujon Hospital; Beaujon Hospital
Enrolling by invitation - verified December 2011 - Conditions: Liver Cirrhosis; Fibrosis; Liver Disease; Digestive System Disease
Interventions: Biological: conventional therapy plus MenSC transplantation; Drug: Conventional therapy plus placebo treatment
Sponsors: S-Evans Biosciences Co.,Ltd.; S-Evans Biosciences Co.,Ltd.; Zhejiang University; Zhejiang Armed Police Hospital; Zhenjiang First People's Hospital; General Hospital of Guangzhou Military Command of PLA
Recruiting - verified December 2011 - Conditions: Colorectal Cancer; Colorectal Polyps
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011 - Condition: Gastrointestinal Diseases
Intervention:
Sponsors: University of California, Irvine; University of California, Irvine
Enrolling by invitation - verified December 2011 - Condition: Gastroesophageal Reflux Disease
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Condition: Stage IV Pancreatic Cancer
Interventions: Biological: VXM01; Biological: Placebo
Sponsors: Vaximm GmbH; Vaximm GmbH
Recruiting - verified December 2011 - Condition: Gastric Cancer
Intervention: Drug: S-1
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Recruiting - verified December 2011 - Condition: Crohn's Disease
Intervention: Drug: GSK1605786
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011 - Conditions: Colon Cancer; Rectal Cancer; Colonic Diverticulosis
Interventions: Drug: Fentanyl; Drug: Propofol; Drug: Midazolam
Sponsors: Saint Joseph Mercy Health System; Saint Joseph Mercy Health System
Recruiting - verified December 2011 - Condition: Barrett's Esophagus
Intervention:
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified December 2011 - Condition: Pancreatic Cancer
Intervention: Drug: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute
Recruiting - verified December 2011 - Condition: Hepatitis C
Interventions: Drug: PSI-352938; Drug: PSI-7977
Sponsors: Pharmasset; Pharmasset
Recruiting - verified December 2011 - Conditions: Breast Cancer; Gastrointestinal Cancer
Intervention: Behavioral: questionnaire and interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Colorectal Carcinoma
Interventions: Drug: axitinib; Drug: placebo
Sponsors: Spanish Cooperative Group for Gastrointestinal Tumour Therapy; Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Recruiting - verified February 2012 - Condition: Ulcerative Colitis
Interventions: Drug: tralokinumab; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca; MedImmune Ltd
Recruiting - verified May 2012 - Condition: Stage IV Colon Cancer
Intervention: Procedure: Oophrectomy
Sponsors: Gachon University Gil Medical Center; Gachon University Gil Medical Center
Recruiting - verified January 2012 - Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: imatinib mesylate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Breast Cancer; Colon Cancer; Lung Cancer; Neuroblastoma; Testicular Cancer
Interventions: Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Colorectal Cancer Metastatic
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2012 - Conditions: Gastroenteritis; Diarrhea
Intervention: Drug: Bio-three
Sponsors: Kaohsiung Veterans General Hospital.; Kaohsiung Veterans General Hospital.; National Yang Ming University
Completed - verified November 2011 - Condition: Colon Neoplasms
Interventions: Procedure: Single-port; Procedure: Multi-port
Sponsors: The Catholic University of Korea; The Catholic University of Korea
Enrolling by invitation - verified November 2011 - Conditions: Gastroesophageal Reflux Disease; Eosinophilic Esophagitis; Dysphagia
Intervention: Drug: dexlansoprazole
Sponsors: Mayo Clinic; Mayo Clinic
Withdrawn - verified April 2012 - Condition: Advanced Esophageal Carcinoma
Intervention: Drug: mFOLFIRI+Nimotuzumab
Sponsors: Peking University; Peking University
Recruiting - verified November 2011 - Condition: Ulcerative Colitis
Interventions: Other: Control; Drug: Probiotic
Sponsors: Postgraduate Institute of Medical Education and Research; Postgraduate Institute of Medical Education and Research; Ministry of Science and Technology, India
Recruiting - verified November 2011 - Condition: Hepatic Metastasis Secondary to Colorectal Cancer
Intervention: Other: Evaluate the correlation of overall different objective response.
Sponsors: Grupo Espanol Multidisciplinario del Cancer Digestivo; Grupo Espanol Multidisciplinario del Cancer Digestivo
Recruiting - verified December 2011 - Condition: Gastric Cancer
Intervention: Drug: RAD001
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2012 - Condition: Celiac Disease
Intervention: Other: Detection of gluten in feces
Sponsors: University of Seville; University of Seville; Instituto Hispalense de Pediatría, Seville, Spain
Completed - verified November 2011 - Condition: Dysphagia
Intervention: Other: speech therapy
Sponsors: Federal University of São Paulo; Federal University of São Paulo
Recruiting - verified December 2011 - Conditions: Familial Adenomatous Polyposis; Attenuated Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Vitkovice Hospital; Vitkovice Hospital
Completed - verified November 2011 - Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Pancreatic Fistula
Interventions: Device: Tachocomb; Device: Polyglycolic acid (PGA) (Neoveil)
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified March 2012 - Condition: Bile Duct Diseases
Intervention: Device: Primary cannulation/precut sphincterotomie with the Baby-S
Sponsors: Ruhr University of Bochum; Ruhr University of Bochum
Completed - verified December 2011 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib; Procedure: TACE for HCC with portal vein invasion
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Not yet recruiting - verified November 2011 - Condition: Digestive System Diseases
Interventions: Drug: Placebo; Drug: CJ-12406
Sponsors: CJ Cheiljedang Corporation; CJ Cheiljedang Corporation
Recruiting - verified December 2011 - Condition: Colorectal Cancer
Interventions: Behavioral: Physician chart reminder; Behavioral: usual care; Behavioral: chart reminder, mailed education, FIT; Behavioral: chart reminder, mailed education, FIT, telephone call
Sponsors: University of Iowa; University of Iowa; American Cancer Society
Active, not recruiting - verified November 2011 - Condition: Colonic Neoplasms
Interventions: Dietary Supplement: citogenex; Other: conventional therapy
Sponsors: University of Palermo; University of Palermo
Not yet recruiting - verified November 2011 - Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: FOLFIRINOX; Genetic: Immunohistochemistry (IHC) Analysis; Drug: Metformin
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team
Recruiting - verified March 2012 - Condition: Colon Cancer
Intervention:
Sponsors: University of Arkansas; University of Arkansas; Genomic Health
Recruiting - verified November 2011 - Conditions: Colon Cancer; Inflammatory Bowel Diseases; Diverticulitis
Interventions: Drug: Spinal analgesia; Drug: Patient Control Analgesia (PCA) Morphine
Sponsors: McGill University Health Center; McGill University Health Center
Completed - verified November 2011 - Condition: Colorectal Neoplasms
Interventions: Dietary Supplement: Synbiotics; Dietary Supplement: Placebo
Sponsors: University of Athens; University of Athens
Recruiting - verified November 2011 - Condition: Hepatocellular Carcinoma
Intervention:
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified February 2012 - Conditions: Obesity; Non-alcoholic Fatty Liver Disease (NAFLD)
Intervention: Other: nutrition counselling
Sponsors: University Hospital, Geneva; University Hospital, Geneva
Recruiting - verified November 2011 - Conditions: Non Alcoholic Fatty Liver Disease; Obstructive Sleep Apnea
Intervention: Device: CPAP (ResMed S9 autoset CPAP)
Sponsors: Johns Hopkins University; Johns Hopkins University; ResMed Foundation
Recruiting - verified November 2011 - Condition: Dysphagia
Intervention: Procedure: PEG tube placement
Sponsors: Helsinki University; Helsinki University
Completed - verified November 2011 - Conditions: Rectal Cancer; Quality of Life; Surgery
Intervention:
Sponsors: Sahlgrenska University Hospital, Sweden; Sahlgrenska University Hospital, Sweden; Swedish Cancer Foundation; The Swedish Society of Medicine; Assar Gabrielsson Foundation; The Gothenburg Medical Society
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Biological: ganitumab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Cognitive/Functional Effects; Constipation, Impaction, and Bowel Obstruction; Diarrhea; Fatigue; Gastrointestinal Complications; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: live freeze-dried lactic acid bacteria probiotic; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: SSP-002358 (0.1 mg) + PPI; Drug: SSP-002358 (0.5 mg) + PPI; Drug: SSP-002358 (2.0 mg) + PPI; Drug: Placebo + PPI
Sponsors: Shire-Movetis NV; Shire-Movetis NV
Recruiting - verified May 2012 - Conditions: Hepatocellular Carcinoma; Renal Cell Carcinoma
Intervention:
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified November 2011 - Condition: Colon Cancer
Intervention:
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified November 2011 - Condition: Wilson Disease
Intervention: Drug: Once a day Trientine
Sponsors: Yale University; Yale University; Valeant Pharmaceuticals International, Inc.
Completed - verified November 2011 - Condition: Metastatic Esophageal Squamous Cell Carcinoma
Intervention:
Sponsors: Samsung Medical Center; Samsung Medical Center
Not yet recruiting - verified February 2012 - Condition: Rectal Cancer
Intervention: Drug: intensified preoperative chemotherapy
Sponsors: Institute of Oncology Ljubljana; Institute of Oncology Ljubljana
Recruiting - verified December 2011 - Condition: Rectal Cancer
Interventions: Drug: Irinotecan; Drug: Capecitabine; Radiation: Radiotherapy
Sponsors: Fudan University; Fudan University
Recruiting - verified November 2011 - Condition: Rectal Cancer
Interventions: Radiation: Radiation therapy; Drug: Oxaliplatin; Drug: Raltitrexed; Drug: levofolinic acid; Drug: 5-fluorouracil; Drug: Bevacizumab
Sponsors: National Cancer Institute, Naples; National Cancer Institute, Naples
Active, not recruiting - verified November 2011 - Conditions: Adenocarcinoma; Stomach Neoplasms
Intervention: Procedure: Extensive Intraperitoneal Lavage (EIPL)
Sponsors: University Hospital Mannheim; University Hospital Mannheim; University of Heidelberg
Recruiting - verified November 2011 - Conditions: Adenocarcinoma of the Pancreas; Metastatic Disease
Intervention: Drug: AUY922
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Novartis Pharmaceuticals
Not yet recruiting - verified January 2012 - Condition: Esophageal Cancer
Intervention:
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM)
Recruiting - verified November 2011 - Condition: Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Interventions: Drug: Capecitabine/Cisplatin(XP); Drug: Capecitabine/Paditaxel(XG)
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified November 2011 - Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Behavioral: geriatric assessment and telephone call from nurse; Other: geriatric assessment and no call from nurse
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Ligation of Intersphincteric Fistula Tract (LIFT) Versus LIFT-plug Procedure for Anal Fistula RepairConditions: Anorectal Fistula; Extracellular Matrix Alteration
Interventions: Procedure: LIFT-plug; Procedure: LIFT
Sponsors: Beijing Chao Yang Hospital; Zhen Jun Wang; Peking University Third Hospital; Tianjin Third Central Hospital; Xi’an Jiaotong University College of Medicine; Shaanxi Provincial People's Hospital
Recruiting - verified November 2011 - Conditions: Postoperative Pancreatic Fistula; Delayed Gastric Emptying
Interventions: Procedure: pancreaticoduodenectomy without Braun enteroenterostomy; Procedure: Braun enteroenterostomy
Sponsors: Johns Hopkins University; Johns Hopkins University
Recruiting - verified November 2011 - Condition: Colorectal Cancer Metastatic
Intervention: Drug: Chemotherapy
Sponsors: University of Florida; University of Florida
Recruiting - verified February 2012 - Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Neuroendocrine Tumor
Intervention: Dietary Supplement: Resveratrol
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012 - Condition: Hepatitis C Virus Infection, Response to Therapy of
Interventions: Drug: JTK-853; Drug: Dose 2 JTK-853; Drug: Dose 3 JTK-853; Drug: Dose 4 JTK-853; Drug: Placebo
Sponsors: Akros Pharma Inc.; Akros Pharma Inc.
Completed - verified November 2011 - Conditions: Ovarian Cancer; Hypodontia; Breast Cancer; Colon Cancer
Intervention:
Sponsors: University of Aarhus; University of Aarhus; Danish Cancer Society
Active, not recruiting - verified November 2011 - Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Adenomatous Polyps
Intervention: Behavioral: 30 minutes of walking (=10,000 steps per day) for 3 months
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Completed - verified November 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Chemotherapy; Drug: Chemotherapy and ChemoRadiotherapy
Sponsors: University of Florida; University of Florida
Recruiting - verified February 2012 - Condition: Gastric Cancer
Intervention:
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified July 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Sarcoma; Stomach Neoplasms; Neoplasms
Interventions: Drug: Pazopanib; Drug: ARQ 197
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Crohn's Disease; Ulcerative Colitis
Intervention:
Sponsors: Hvidovre University Hospital; Hvidovre University Hospital; Ferring Pharmaceuticals; Merck
Enrolling by invitation - verified November 2011 - Conditions: Metastatic Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma
Intervention: Drug: Gemcitabine/Docetaxel
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified November 2011 - Conditions: Ovarian Cancer; Pancreatic Cancer
Intervention: Drug: DMOT4039A
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Colorectal Carcinoma
Intervention: Biological: JX-594
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified November 2011 - Conditions: Rectal Cancer; Liver Metastasis
Interventions: Procedure: MR colonography and MR of the liver; Procedure: Standard diagnostic evaluation
Sponsors: Herlev Hospital; Herlev Hospital
Recruiting - verified February 2012 - Condition: Colorectal Cancer
Interventions: Drug: Axitinib; Drug: Bevacizumab; Drug: 5-FU; Drug: 5-FU; Drug: Leucovorin; Drug: Oxaliplatin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Pfizer
Recruiting - verified January 2012 - Condition: Gastric Cancer
Interventions: Drug: XELOX; Drug: XELODA
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified November 2011 - Condition: Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma
Intervention: Drug: oxaliplatin
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified November 2011 - Conditions: Colorectal Cancer; Colon Rectal Resection; Oxidative Stress
Intervention: Procedure: Surgery for colorectal cancer
Sponsors: G. Hatzikosta General Hospital; G. Hatzikosta General Hospital; University of Ioannina
Completed - verified November 2011 - Conditions: Gastrointestinal Diseases; Digestive System Diseases
Interventions: Other: air insufflation; Other: warm water irrigation
Sponsors: Presidio Ospedaliero Santa Barbara; Presidio Ospedaliero Santa Barbara
Recruiting - verified January 2012 - Conditions: Colorectal Cancer; Breast Cancer; Coronary Heart Disease; Diabetes
Intervention: Other: risk assessment survey; decision support for providers for prevention based on risk
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Not yet recruiting - verified May 2012 - Conditions: Esophageal Atresia With Tracheo-esophageal Fistula; Congenital Diaphragmatic Hernia
Interventions: Procedure: Hypercapnia during thoracoscopy; Procedure: Open surgery
Sponsors: Great Ormond Street Hospital for Children NHS Trust; Great Ormond Street Hospital for Children NHS Trust
Recruiting - verified November 2011 - Condition: Gastric Cancer
Interventions: Drug: Capecitabine; Drug: capecitabine
Sponsors: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Recruiting - verified November 2011 - Conditions: Rotavirus Infections; Gastroenteritis; Diarrhea
Intervention:
Sponsors: McGill University Health Center; McGill University Health Center; Centre hospitalier universitaire Sainte-Justine; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier régional de Rimouski; Institut National en Santé Publique du Québec; Ministère de la santé et des services sociaux; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Irritable Bowel Syndrome; Panic Disorder
Intervention: Drug: Escitalopram
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center
Recruiting - verified March 2012 - Condition: Crohn Disease
Interventions: Other: Endoscopy; Other: Endoscopy
Sponsors: University of Bern; University of Bern; University Hospital, Basel, Switzerland; University of Lausanne Hospitals; Swiss IBD Cohort Study; MSD Merck Sharp & Dohme AG
Active, not recruiting - verified November 2011 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: Placebo; Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Stomach Neoplasm
Intervention: Drug: RAD001
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified November 2011 - Conditions: Solid Tumor of Epithelial Origin; Gastric Cancer
Interventions: Drug: AbGn-7; Drug: AbGn-7
Sponsors: AbGenomics B.V Taiwan Branch; AbGenomics B.V Taiwan Branch
Recruiting - verified December 2011 - Condition: Nonalcoholic Steatohepatitis
Interventions: Biological: IMM 124-E; Biological: Placebo
Sponsors: Immuron Ltd.; Immuron Ltd.
Not yet recruiting - verified March 2012 - Condition: Crohn's Disease
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Biliary Diseases; Pancreas Diseases
Interventions: Procedure: Team 1; Procedure: Team 2
Sponsors: Zhejiang University; Qi-yong Li
Completed - verified May 2012 - Condition: End Stage Liver Disease
Intervention:
Sponsors: The Methodist Hospital System; R. Mark Ghobrial, MD; Novartis
Enrolling by invitation - verified October 2011 - Condition: Duodenal Ulcer Bleeding
Intervention: Procedure: prophylactic injection therapy
Sponsors: Bakirkoy Dr. Sadi Konuk Research and Training Hospital; Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Completed - verified November 2011 - Condition: Colon Cancer Liver Metastasis
Interventions: Drug: Lyso-Thermosensitive Liposomal Doxorubicin; Other: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified March 2012 - Condition: Colorectal Cancer, Metastatic
Interventions: Other: Pharmacokinetic 5-FU dose adjustment using OnDose® assay; Other: Standard of care
Sponsors: Myriad Genetic Laboratories, Inc.; Myriad Genetic Laboratories, Inc.
Recruiting - verified February 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: Gemcitabine + Capecitabine
Sponsors: Vejle Hospital; Vejle Hospital
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Procedure: curative resection for colorectal cancer; Drug: intra-operative 5-FU chemotherapy
Sponsors: Sun Yat-sen University; Sun Yat-sen University
Recruiting - verified November 2011 - Conditions: Gastric Cancer; Metastases to Perineum
Interventions: Drug: Oxaliplatin; Drug: Paclitaxel
Sponsors: Peking University; Peking University
Recruiting - verified November 2011 - Conditions: Short Segment Barrett's Esophagus; Long Segment Barrett's Esophagus
Interventions: Drug: Omeprazole; Drug: Vitamin D3; Drug: Vitamin D3; Procedure: upper endoscopy
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified May 2012 - Conditions: Inflammatory Bowel Disease; Colorectal Cancer
Intervention:
Sponsors: UMC Utrecht; UMC Utrecht; Merck; Ferring Pharmaceuticals
Recruiting - verified October 2011 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: Nexium®; Drug: Esomeprazol (40mg) + Sdium Bicarbonate (721mg)
Sponsors: Eurofarma Laboratorios S.A.; Eurofarma Laboratorios S.A.
Not yet recruiting - verified November 2011 - Conditions: Solitary Pulmonary Nodules; Multiple Pulmonary Nodules; Renal Neoplasms; Adrenal Gland Neoplasms; Aortic Aneurysm, Abdominal; Liver Neoplasms; Adnexal and Skin Appendage Neoplasms; Lymphadenopathy; Pancreatic Neoplasms
Intervention:
Sponsors: American College of Radiology Imaging Network; American College of Radiology Imaging Network; ACRIN Foundation
Enrolling by invitation - verified November 2011 - Condition: Depression
Interventions: Drug: Mirtazapine; Other: Supportive psychotherapy
Sponsors: Seoul National University Boramae Hospital; Seoul National University Boramae Hospital
Recruiting - verified October 2011 - Condition: Colorectal Carcinoma
Intervention: Drug: axitinib
Sponsors: Institut Gustave Roussy; Institut Gustave Roussy
Recruiting - verified November 2011 - Conditions: Renal Cell Carcinoma; Hepatocellular Carcinoma
Intervention: Procedure: skin punch biopsy
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified March 2012 - Condition: Esophageal Cancer
Intervention: Drug: Nimotuzumab
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Active, not recruiting - verified October 2011 - Conditions: Gastric Cancer; Colon Cancer
Intervention: Device: Endoscopic submucosal dissection (ESD) using device, MASTER
Sponsors: National University Hospital, Singapore; National University Hospital, Singapore; Prince of Wales Hospital, Shatin, Hong Kong; Apollo Gleneagles Hospitals, Kolkata, India
Not yet recruiting - verified October 2011 - Conditions: Acute Diarrhea; Acute Gastroenteritis
Interventions: Dietary Supplement: Probiotic yogurt; Drug: Placebo probiotic
Sponsors: Centro Pediatrico Albina de Patino; Centro Pediatrico Albina de Patino
Completed - verified March 2012 - Condition: Chronic Hepatic Impairment
Intervention: Drug: Preladenant
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012 - Conditions: Constipation; Irritable Bowel Syndrome
Interventions: Dietary Supplement: B. lactis HN019; Dietary Supplement: B. lactis HN019; Dietary Supplement: Placebo
Sponsors: Fonterra Research Centre; Fonterra Research Centre; Danisco Sweeteners Oy
Not yet recruiting - verified December 2011 - Condition: Advanced Gastric Cancer
Intervention: Drug: Clinical chemo-drugs
Sponsors: Peking University; Peking University
Not yet recruiting - verified November 2011 - Condition: Crohn's Disease
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Enrolling by invitation - verified May 2012 - Conditions: Colon Carcinoma; Rectum Carcinoma
Interventions: Biological: L-BLP25; Biological: Placebo
Sponsors: Johannes Gutenberg University Mainz; Dr. Carl Schimanski
Recruiting - verified April 2012 - Conditions: Lung Cancer; Colorectal Cancer; Breast Cancer
Intervention: Drug: Cancer Stem Cells Sensitivity Assay
Sponsors: Associazione Oncologia Traslazionale; Associazione Oncologia Traslazionale
Active, not recruiting - verified November 2011 - Condition: Diarrhea
Interventions: Dietary Supplement: oral rehydration solution Hipp ORS Apple 200; Dietary Supplement: ESPGHAN ORS
Sponsors: Medical University of Warsaw; Medical University of Warsaw
Recruiting - verified November 2011 - Conditions: Respiratory Distress Syndrome, Adult; Gastrointestinal Hemorrhage; Liver Diseases; Blood Component Transfusion
Interventions: Other: Transfuse plasma to INR target; Other: Transfuse plasma to INR target
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified October 2011 - Condition: Gastric Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab; Drug: cisplatin; Drug: capecitabine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Genital Diseases, Female; Ovarian Diseases; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
Interventions: Biological: Bevacizumab; Biological: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin; Other: specialized pathology review (Germany only)
Sponsors: AGO Study Group; AGO Study Group; ARCAGY/ GINECO GROUP; Nordic Society for Gynaecologic Oncology
Recruiting - verified November 2011 - Conditions: Celiac Disease; Neurobehavioral Manifestations
Interventions: Dietary Supplement: gluten; Dietary Supplement: Placebo
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Not yet recruiting - verified February 2012 - Conditions: Esophageal Cancer; Neoplasms, Esophageal
Interventions: Drug: Everolimus; Drug: Paclitaxel; Drug: carboplatin; Drug: cetuximab
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified March 2012 - Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
Sponsors: Technische Universität München; Technische Universität München
Recruiting - verified October 2011 - Condition: Metastatic Colorectal Cancer
Intervention:
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Limited, UK
Recruiting - verified December 2011 - Condition: Colorectal Cancer
Intervention: Biological: FSP peptides
Sponsors: Oryx GmbH & Co. KG; Oryx GmbH & Co. KG
Recruiting - verified February 2012 - Condition: Colon Cancer
Intervention: Procedure: timing to initiate the adjuvant chemotherapy
Sponsors: Kyungpook National University; Kyungpook National University
Enrolling by invitation - verified November 2011 - Condition: Carcinoma of the Oesophagus
Interventions: Drug: Olaparib; Radiation: Radical external beam radiotherapy, 50Gy in 25 fractions
Sponsors: Christie Hospital NHS Foundation Trust; Christie Hospital NHS Foundation Trust; Cancer Research UK (New Agents Committee); AstraZeneca
Not yet recruiting - verified December 2011 - Condition: Non-erosive Gastroesophageal Reflux Disease
Interventions: Drug: TAK-438; Drug: TAK-438; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified May 2012 - Condition: Liver Diseases
Intervention:
Sponsors: University Hospital, Lille; University Hospital, Lille
Recruiting - verified March 2012 - Condition: Hepatitis C Virus Infection
Interventions: Drug: JNJ-47910382; Drug: JNJ-47910382; Drug: JNJ-47910382; Drug: JNJ-47910382; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Completed - verified May 2012 - Conditions: Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified November 2011 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach
Interventions: Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab; Drug: Post-operative treatment trastuzumab mono therapy
Sponsors: AIO-Studien-gGmbH; AIO-Studien-gGmbH; Roche Pharma AG
Recruiting - verified January 2012 - Condition: Barrett's Esophagus
Intervention: Device: Polar Wand carbon dioxide cryotherapy
Sponsors: Mayo Clinic; Mayo Clinic; Chek-Med Systems, Inc.
Enrolling by invitation - verified November 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Taxotere; Drug: Xeloda; Drug: Cisplatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011 - Conditions: ColoRectal Cancer; Colonic Pre-malignant Polyps
Intervention: Device: The P1 Check-Cap capsule
Sponsors: Ceck Cap Ltd.; Ceck Cap Ltd.
Not yet recruiting - verified October 2011 - Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Perianal Fistulas
Intervention: Device: KULIST
Sponsors: Nordic Drugs AB; Nordic Drugs AB
Recruiting - verified February 2012 - Condition: Rectal Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified November 2011 - Condition: Gastric Cancer
Interventions: Drug: Docetaxel; Drug: cisplatin; Drug: Capecitabine; Procedure: D1extra-resection
Sponsors: Jeroen Bosch Ziekenhuis; Jeroen Bosch Ziekenhuis; Eindhoven Cancer Registry
Recruiting - verified January 2012 - Condition: Pancreatic Cancer
Interventions: Radiation: Proton Therapy; Drug: Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Condition: Bile Duct Neoplasms Malignant
Interventions: Procedure: ERCP with 10 French biliary plastic stent placement; Procedure: ERCP with 11.5 French biliary plastic stent
Sponsors: Indiana University; Indiana University; American Society for Gastrointestinal Endoscopy; American College of Gastroenterology
Completed - verified October 2011 - Condition: Rectal Cancer
Interventions: Procedure: Abdominoperineal resection; Procedure: Intersphincteric resection
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Seoul National University Bundang Hospital; National Cancer Center, Korea
Recruiting - verified November 2011 - Conditions: Pancreatic Tumor; Fine Needle Aspiration; Endoscopic Ultrasonography
Intervention: Procedure: Puncture with fine needle aspiration under endoscopic ultrasonographic control
Sponsors: Société Française d'Endoscopie Digestive; VANBIERVLIET
Recruiting - verified October 2011 - Condition: Irritable Bowel Syndrome
Intervention:
Sponsors: Danone Research; Danone Research
Recruiting - verified October 2011 - Conditions: Malignant Solid Tumour; Breast Cancer; Ovarian Cancer; Colorectal Cancer
Intervention: Drug: NKTR-102
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Available - verified April 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Completed - verified October 2011 - Conditions: Peritoneal Contamination After Ileocolonic Anastomosis; Wound Infection; Intra-abdominal Abscess
Interventions: Procedure: Stapled anastomosis; Procedure: Handsewn anastomosis
Sponsors: Hospital General Universitario Elche; Hospital General Universitario Elche
Not yet recruiting - verified October 2011 - Condition: Adenocarcinoma Pancreas
Interventions: Other: Gemcitabine; Drug: CP-870,893
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting - verified March 2012 - Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Biological: ipilimumab; Drug: gemcitabine hydrochloride; Other: laboratory biomarker analysis
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Not yet recruiting - verified November 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Neoadjuvant chemoradiation; Procedure: Upfront surgery
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified February 2012 - Condition: Adenocarcinoma of the Colon
Interventions: Drug: Tinzaparin; Drug: Tinzaparin
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011 - Conditions: Hepatitis C; Human Immunodeficiency Virus (HIV)
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Active, not recruiting - verified April 2012 - Conditions: Colon Cancer; Rectal Cancer
Interventions: Behavioral: surveys; Behavioral: surveys; Behavioral: surveys; Behavioral: Surveys
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Other: Treatment with chemotherapy; Other: Only chemotherapy treatment for study cohort; Procedure: surgery
Sponsors: Centro Hospitalar Nordeste; Centro Hospitalar Nordeste
Completed - verified September 2008 - Condition: Pancreatic Tumors
Interventions: Procedure: Standard; Procedure: Fanning
Sponsors: University of Alabama at Birmingham; Shyam Varadarajulu
Completed - verified February 2012 - Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic TumorsCondition: Pancreatic Tumors
Interventions: Procedure: EUS Guided Fine Needle Aspiration; Procedure: EUS Guided EchoBrush Sampling
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; American Cancer Society
Recruiting - verified April 2012 - Condition: Gastric Cancer
Interventions: Drug: s1; Drug: Oxaliplatin
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified February 2012 - Conditions: Anxiety Disorder; Breast Cancer; Cancer Survivor; Cognitive/Functional Effects; Colorectal Cancer; Depression; Fatigue; Pain; Psychosocial Effects of Cancer and Its Treatment; Weight Changes
Interventions: Behavioral: behavioral dietary intervention; Behavioral: compliance monitoring; Behavioral: exercise intervention; Genetic: DNA methylation analysis; Other: counseling intervention; Other: laboratory biomarker analysis; Other: preventative dietary intervention; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Condition: Colorectal Neoplasms
Intervention: Behavioral: Reminder and Outreach Intervention
Sponsors: Northwestern University; Northwestern University; Agency for Healthcare Research and Quality (AHRQ)
Enrolling by invitation - verified March 2012 - Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: PEGPH20+ gemcitabine
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified March 2012 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel); Drug: Gemcitabine
Sponsors: ParinGenix; ParinGenix; TGen Drug Development Services
Recruiting - verified April 2012 - Condition: Gastroesophageal Reflux Disease
Intervention: Procedure: Full-Thickness-Gastroplication
Sponsors: General Public Hospital Zell am See; General Public Hospital Zell am See
Recruiting - verified October 2011 - Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer
Intervention: Drug: CDX-1127
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Conditions: Healthy; Hepatic Impairment
Intervention: Drug: cabozantinib
Sponsors: Exelixis; Exelixis
Recruiting - verified December 2011 - Condition: Gastric Cancer
Interventions: Procedure: Laparoscopic gastrectomy; Procedure: Open gastrectomy
Sponsors: Ajou University School of Medicine; Ajou University School of Medicine
Recruiting - verified March 2012 - Condition: Advanced Pancreatic Carcinoma
Interventions: Drug: gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.; Drug: Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI
Sponsors: Centro Nacional de Investigaciones Oncologicas CARLOS III; Centro Nacional de Investigaciones Oncologicas CARLOS III; Hospital Universitario Fuenlabrada; Apices Soluciones S.L.; Grupo Hospital de Madrid
Recruiting - verified April 2012 - Conditions: Gastroesophageal Varices Hemorrhage; Hepatocellular Carcinoma
Intervention: Drug: propranolol
Sponsors: Taipei Veterans General Hospital,Taiwan; Taipei Veterans General Hospital,Taiwan
Recruiting - verified October 2011 - Condition: Rectal Carcinoma
Interventions: Radiation: Radiotherapy; Radiation: Radiotherapy
Sponsors: International Atomic Energy Agency; International Atomic Energy Agency; Centre Anti Cancer Hopital Frantz Fanon; Hospital A.C. Camargo; Credit Valley Hospital; Instituto Nacional de Cancerologia, Columbia; University Hospital "Sestre milosrdnice"; Minesterio de Cienca, Tecnologia y Medio Ambiente; V.N. Cancer Center GKNM Hospital; Tata Memorial Hospital; Dr. Cipto Mangunkusumo National General Hospital; National Cancer Center, Bratislava; University of Cape Town; Catholic University of the Sacred Heart
Recruiting - verified October 2011 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
Interventions: Drug: MM-121 (SAR256212); Drug: Irinotecan; Drug: Cetuximab
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Colorectal Cancer (CRC)
Intervention: Drug: Cetuximab
Sponsors: Merck KGaA; Merck KGaA; Merck, S.L., Spain
Recruiting - verified October 2011 - Condition: Pancreatic Cancer
Intervention: Drug: Vitamin E δ-Tocotrienol
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); BioGene Life Science
Recruiting - verified March 2012 - Conditions: Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Interventions: Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation A; Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation B; Biological: Infanrix hexaTM; Biological: Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine (Prevenar 13®)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: pegylated liposomal doxorubicin hydrochloride; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Esophageal Cancer; Precancerous Condition
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Colorectal Cancer; Inflammation
Intervention: Dietary Supplement: fish oil encapsuled
Sponsors: Universidade Federal de Santa Catarina; Universidade Federal de Santa Catarina; Centro de Pesquisas Oncológicas de Florianópolis; Fundação de Amparo a Pesquisa e Inovação do Estado de Santa Catarina; Programa de Pós-Graduação em Nutrição da Universidade Federal de Santa Catarina
Recruiting - verified April 2012 - Conditions: Bladder Cancer; Colorectal Cancer; Endometrial Cancer; Kidney Cancer; Skin Cancer; Uterus Cancer
Intervention: Behavioral: Health and Diet Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma; Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide; Drug: pazopanib hydrochloride
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified November 2011 - Conditions: Coronary Artery Disease; Congestive Heart Failure; Valvular Heart Disease; Atrial Fibrillation; Hypertension; Pyelonephritis; Acute Renal Failure; Renal Failure; Viral Hepatitis; Alcoholic Hepatitis; Steatohepatitis; Cirrhosis; Asthma; COPD; Bronchitis; Emphysema; Pneumonia; Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; Diverticulitis; Peptic Ulcer Disease; Irritable Bowel Syndrome; Cholecystitis; Pancreatitis; Malabsorption Disorders; Celiac Sprue; Diabetes
Intervention:
Sponsors: Epic Research & Diagnostics, Inc.; Epic Research & Diagnostics, Inc.
Completed - verified November 2011 - Conditions: Obesity; Non-alcoholic Fatty Liver Disease
Interventions: Dietary Supplement: Resveratrol; Other: Placebo; Other: No intervention
Sponsors: University of Aarhus; University of Aarhus; The Ministry of Science, Technology and Innovation, Denmark
Recruiting - verified February 2012 - Conditions: Metabolic Syndrome; Non Alcoholic Fatty Liver Disease; Insulin Resistance
Interventions: Dietary Supplement: glucomannan; Behavioral: lifestyle intervention
Sponsors: Bambino Gesù Hospital and Research Institute; Bambino Gesù Hospital and Research Institute
Recruiting - verified March 2012 - Conditions: Meningococcal Disease; Meningococcal Meningitis; Hepatitis A; Hepatitis B
Interventions: Biological: MenACWY-CRM; Biological: Combined inactivated hepatitis A and recombinant hepatitis B vaccine; Biological: Recombinant hepatitis B vaccine; Biological: Inactivated hepatitis A vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Completed - verified March 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: MM-121 (SAR256212) + Paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Esophageal Motility Disorders
Interventions: Drug: Azithromycin; Drug: Placebo
Sponsors: Queen Mary University of London; JAFAR JAFARI
Not yet recruiting - verified October 2011 - Conditions: Esophageal Cancer; Stomach Cancer; Pancreatic Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Post-operative Pneumonia; Lung Cancer; Esophageal Cancer
Intervention: Procedure: Intensive Brushing Regimen
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Fallopian Tube Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2); Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: study of socioeconomic and demographic variables; Procedure: disease screening; Procedure: evaluation of cancer risk factors; Procedure: genitourinary surgical procedure; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified September 2011 - Conditions: Solid Tumour; Adenocarcinoma of the Colon; Adenocarcinoma of the Pancreas
Intervention: Drug: CEP-37250/KHK2804
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Cephalon
Recruiting - verified February 2012 - Condition: Fatty Liver
Interventions: Dietary Supplement: Resveratrol; Dietary Supplement: Placebo
Sponsors: University of Aarhus; University of Aarhus; The Ministry of Science, Technology and Innovation, Denmark; Aarhus University Hospital
Recruiting - verified December 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Conditions: Nasopharyngeal Carcinoma; Hepatocellular Carcinoma; Breast Carcinoma
Intervention: Biological: tumor infiltrating lymphocytes, IL-2
Sponsors: Sun Yat-sen University; Sun Yat-sen University
Recruiting - verified November 2011 - Conditions: Anemia; Breast Cancer; Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Rectal Cancer
Interventions: Radiation: Preoperative radiotherapy; Procedure: Surgery
Sponsors: Jagiellonian University; Jagiellonian University
Completed - verified September 2011 - Condition: Gastric Cancer
Intervention:
Sponsors: Haydarpasa Numune Training and Research Hospital; Haydarpasa Numune Training and Research Hospital
Active, not recruiting - verified September 2011 - Conditions: Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: sphingosine kinase-2 inhibitor ABC294640
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Apogee Biotechnology Corporation; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Neoplasms; Gastric Cancer
Intervention: Procedure: Standard of Care Procedure as described in ARM
Sponsors: Mayo Clinic; Mayo Clinic; US Endoscopy
Recruiting - verified November 2011 - Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Condition: Recurrent Gastrointestinal Symptoms
Interventions: Dietary Supplement: Trenev Trio®/Healthy Trinity®; Dietary Supplement: Placebo
Sponsors: Sprim Advanced Life Sciences; Sprim Advanced Life Sciences; The National Institute of Probiotics
Recruiting - verified December 2011 - Condition: Esophageal Cancer
Intervention: Drug: paclitaxel and cisplatin
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences; Beijing Municipal Science & Technology Commission
Recruiting - verified October 2011 - Condition: Dysphagia With Normal Endoscopy
Intervention: Procedure: Dilation of the esophagus
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Enrolling by invitation - verified November 2011 - Condition: Pancreatic Cancer
Intervention: Drug: Vitamin E δ-Tocotrienol
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); BioGene Life Science
Recruiting - verified March 2012 - Condition: Esophageal Motility Disorders
Intervention:
Sponsors: University of Zurich; University of Zurich
Recruiting - verified October 2011 - Condition: Perianal Crohn's Disease
Interventions: Drug: BLI-1300 low dose; Drug: BLI-1300 high dose; Drug: placebo
Sponsors: Braintree Laboratories; Braintree Laboratories
Recruiting - verified December 2011 - Conditions: Hepatitis C; Liver Disease
Interventions: Drug: DEB025 plus peg-IFN alpha 2a and ribavirin fixed duration treatment; Drug: DEB025 plus peg-IFN alpha 2a and ribavirin response guided treatment duration; Drug: Boceprevir plus peg-IFN alpha 2a and ribavirin per label response guided treatment
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Hepatic Fibrosis; Hepatocellular Carcinoma
Intervention: Procedure: Magnetic resonance elastography and liver biopsy
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Not yet recruiting - verified October 2011 - Conditions: Cancer of Pancreas; Cancer of the Pancreas; Neoplasms, Pancreatic; Pancreas Cancer; Pancreas Neoplasms
Interventions: Drug: Folfirinox; Radiation: Stereotactic Body Radiotherapy (SBRT)
Sponsors: Emory University; Emory University
Recruiting - verified April 2012 - Condition: Gastric Cancer
Intervention: Procedure: Laparoscopic sentinel node navigation surgery
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Recruiting - verified September 2011 - Conditions: Advanced Gastric Cancer; Laparoscopic Gastrectomy
Intervention: Procedure: Laparoscopic gastrectomy
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Active, not recruiting - verified May 2012 - Condition: Gastric Cancer
Intervention: Drug: irinotecan and cisplatin
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified September 2011 - Condition: Hepatic Impairment
Intervention: Drug: Iloperidone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: ribavirin
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular
Interventions: Drug: Crizotinib plus VEGF inhibitor combinations; Drug: Crizotinib plus axitinib; Drug: Crizotinib plus sunitinib; Drug: Crizotinib plus axitinib; Drug: Crizotinib plus sunitinib; Drug: Crizotinib plus bevacizumab; Drug: Crizotinib plus sorafenib
Sponsors: Pfizer; Pfizer
Withdrawn - verified December 2011 - Conditions: Pancreas Tumor; Pancreatitis
Interventions: Procedure: No Drains; Procedure: Drains
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Enrolling by invitation - verified September 2011 - Conditions: Human Immunodeficiency Virus Infection; Hepatitis C
Intervention:
Sponsors: G & W Laboratories Inc.; G & W Laboratories Inc.; Alquest; SMART Biotech Ltd
Recruiting - verified October 2011 - Condition: Enteropathy
Interventions: Drug: Albendazole; Drug: Placebo; Dietary Supplement: High-dose Zinc
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Completed - verified March 2012 - Conditions: Prostate Cancer; Breast Cancer; Colorectal Cancer; Thoracic Cancer
Interventions: Other: CIS (Cancer Information Service) Information Sheet; Other: Facing Forward booklet
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Completed - verified September 2011 - Conditions: Obesity; Colon Cancer
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania
Enrolling by invitation - verified October 2011 - Condition: Colon Cancer
Intervention: Drug: Metformin
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified May 2012 - Condition: Barrett`s Esophagus
Interventions: Other: biopsies; Other: biopsy
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz
Recruiting - verified September 2011 - Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal DisordersConditions: Ampullary Cancer; Duodenal Cancer; Bile Duct Cancer; Bile Duct Disorders; Gallstones; Obstructive Jaundice; Pancreatic Disorders (Noncancerous); Colorectal Cancer; Esophageal Cancer; Barrett's Esophagus; Gastric Malignancies; Pancreatic Cancer; Pediatric Gastroenterology; Cholangiocarcinoma; Pancreatic Pseudocysts; Acute and Chronic Pancreatitis; Recurrent Pancreatitis; Cholangitis; Bile Leak; Biliary Strictures; Pancreatic Divisum; Biliary and Pancreatic Stones; Choledocholithiasis
Intervention:
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Active, not recruiting - verified September 2011 - Conditions: Cholangiocarcinoma; Pancreatic Cancer; Bile Duct Cancer; Biliary Stricture; Bile Duct Obstruction
Intervention: Device: Radio Frequency ablation Probe
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Active, not recruiting - verified September 2011 - Condition: Crohn's Disease
Intervention: Drug: Remicade
Sponsors: Mount Sinai School of Medicine; Shradha Agarwal; Prometheus Laboratories
Recruiting - verified December 2011 - Condition: Crohn's Disease
Interventions: Drug: Infliximab; Drug: Infliximab; Drug: Infliximab
Sponsors: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives; Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Not yet recruiting - verified September 2011 - Condition: Celiac Disease
Intervention: Device: MGH Optical Frequency Domain Imaging (OFDI)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Active, not recruiting - verified September 2011 - Condition: Liver Disease
Intervention: Genetic: genotyping and/or sequencing
Sponsors: Casa Sollievo della Sofferenza IRCCS; Casa Sollievo della Sofferenza IRCCS; INMI L Spallanzani IRCCS Roma; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi; Azienda Ospedaliera San Camillo Forlanini; IRCCS Policlinico S. Matteo; Azienda ospedaliera Garibaldi Nesinma Catania; Azienda Ospedaliero-Universitaria Careggi; University of Milan; Catholic University, Italy; Ospedale di Casarano Francesco Ferrari; Ospedale di Canosa di Puglia; Ospedale di Venosa; Clinica Santa Rita Bari; Ospedale SS. Annunziata, Taranto; Ospedali Riuniti di Foggia
Recruiting - verified April 2012 - Conditions: Liver Cancer; Pancreatic Cancer
Interventions: Procedure: Intravenous Patient-Controlled Analgesia (IVPCA); Procedure: Thoracic Epidural Analgesia (TEA); Behavioral: Questionnaires; Behavioral: Pain Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Barrett's Esophagus
Intervention: Device: MGH Optical Frequency Domain Imaging (OFDI) system
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Barrett's Esophagus
Intervention: Device: MGH Optical Frequency Domain Imaging (OFDI) System
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Active, not recruiting - verified September 2011 - Conditions: Solid Tumors; Hepatic Impairment
Intervention: Drug: Dovitinib
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Conditions: Gastro-oesophageal Junction Cancer; Gastric Cancer
Interventions: Drug: AZD4547; Drug: paclitaxel
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Conditions: Colorectal Cancer With Hepatic Metastases; Pancreas Cancer With Hepatic Metastase; Gastric Cancer With Hepatic Metastase; Breast Cancer With Hepatic Metastase; Ovarian Cancer With Hepatic Metastase
Intervention: Drug: TKM-080301
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Colorectal Cancer
Intervention: Drug: bowel prep before endoscopy
Sponsors: Randers Region Hospital; Randers Region Hospital
Recruiting - verified January 2012 - Conditions: Kasai Operation; Biliary Atresia
Interventions: Drug: desflurane anesthetics; Drug: sevoflurane anesthetics
Sponsors: Yonsei University; Yonsei University
Recruiting - verified September 2011 - Condition: Acute Liver Failure
Intervention:
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified September 2011 - Conditions: Colon Cancer; Head and Neck Cancer; Allergic Reaction
Intervention: Other: blood sample
Sponsors: Centre Francois Baclesse; Centre Francois Baclesse; University Hospital, Caen
Recruiting - verified May 2012 - Condition: Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Conditions: Iron Deficiency Anemia; Inflammatory Bowel Disease
Interventions: Drug: Intravenous iron sucrose; Drug: Oral ferrous sulfate
Sponsors: Wayne State University; Wayne State University; Children's Hospital of Michigan; Luitpold Pharmaceuticals
Not yet recruiting - verified September 2011 - Conditions: Colonic Neoplasms; Iron Deficiency Anemia; Diarrhea
Intervention: Device: Olympus ScopeGuide
Sponsors: University of Alberta; Christopher Teshima
Recruiting - verified April 2012 - Conditions: Gastric Ulcer; Duodenal Ulcer; Gastric Mucosa-associated Lymphoid Tissue (MALT); Lymphoma Idiopathic Thrombocytopenic Purpura; Early Gastric Cancer
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Condition: Rectal Neoplasms
Intervention: Radiation: preoperative short-course radiotherapy
Sponsors: West China Hospital; West China Hospital
Recruiting - verified March 2012 - Condition: Crohn's Disease
Intervention: Biological: Trichuris suis ova
Sponsors: Coronado Biosciences, Inc.; Coronado Biosciences, Inc.
Active, not recruiting - verified April 2012 - Conditions: End Stage Liver Disease; Hepatic Encephalopathy
Intervention:
Sponsors: Hospital Israelita Albert Einstein; Hospital Israelita Albert Einstein
Not yet recruiting - verified September 2011 - Condition: Gastrointestinal Tumor
Interventions: Drug: SOM230C LAR; Drug: FOLFIRI Infusion
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Novartis
Recruiting - verified February 2012 - Condition: Colorectal Cancer
Intervention: Procedure: Energy healing
Sponsors: University of Southern Denmark; University of Southern Denmark; University of Aarhus; The Ministry of Science, Technology and Innovation, Denmark
Recruiting - verified February 2012 - Condition: Rectal Cancer
Intervention: Drug: capecitabine, oxaliplatin, bevacizumab
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Pancreatic Tumor
Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT); Radiation: Tissue, Blood, Research Imaging (TBRI)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute
Withdrawn - verified February 2012 - Condition: Crohn's Disease
Interventions: Drug: 80 mg Delayed Release 6 Mercaptopurine; Drug: 80 mg Delayed Release 6 Mercaptopurine
Sponsors: Teva GTC; Teva GTC
Not yet recruiting - verified September 2011 - Conditions: Schizophrenia; Celiac Disease
Intervention: Procedure: Blood Draw
Sponsors: University of Maryland; University of Maryland
Completed - verified March 2012 - Conditions: Atrial Fibrillation; Atrial Premature Complexes
Intervention:
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; Commission for Technology and Innovation of the Swiss Federal Administration
Recruiting - verified April 2012 - Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Synovial Sarcoma; Dermatofibrosarcoma Protuberans; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: pazopanib hydrochloride; Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: placebo; Procedure: therapeutic conventional surgery; Radiation: external beam radiation therapy; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Pancreatic Neoplasms; Cholangiocarcinoma
Intervention: Drug: Gemcitabine with TheraSphere
Sponsors: Emory University; Hyun Kevin Kim; Emory University
Recruiting - verified April 2012 - Conditions: Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Pancreatic Diseases; Digestive System Diseases
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Conditions: Exocrine Pancreatic Insufficiency; Pancreatic Diseases; Digestive System Diseases
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Chronic Liver Disease; Hepatocellular Carcinoma (HCC)
Intervention: Drug: 13C Sodium Octanoate
Sponsors: Exalenz Bioscience LTD.; Exalenz Bioscience LTD.; Toronto General Hospital; Medical University of South Carolina,USA; Northwestern University,USA; Henry Ford Health System,USA; Hadassah Medical Center,Israel
Terminated - verified September 2011 - Conditions: Temperament; Anxiety; Depression; Colorectal Cancer
Intervention:
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Recruiting - verified September 2011 - Condition: Gastric Cancer
Intervention: Procedure: Laparoscopy-assisted gastrectomy
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Not yet recruiting - verified November 2011 - Condition: Gastroesophageal Reflux Disease
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Completed - verified May 2012 - Condition: Esophageal Spasm, Diffuse
Interventions: Drug: Placebo; Drug: Botulinum Toxin Type A
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Recruiting - verified September 2011 - Condition: Small Bowel Disease
Intervention: Device: capsule endoscopy
Sponsors: Given Imaging Ltd.; Given Imaging Ltd.
Recruiting - verified September 2011 - Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: MK-4074 200 mg; Drug: Placebo for MK-4074 100 mg; Drug: Pioglitazone hydrochloride 30 mg; Drug: Placebo for pioglitazone hydrochloride 30 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Interventions: Other: Radiation therapy; Other: Transarterial chemoembolization
Sponsors: Asan Medical Center; Asan Medical Center
Not yet recruiting - verified September 2011 - Condition: Liver Diseases
Intervention: Drug: Movicol
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center; Norgine
Not yet recruiting - verified September 2011 - Condition: Ulcerative Colitis
Intervention: Drug: Trichuris suis ova
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified December 2011 - Condition: Rectal Cancer
Intervention: Radiation: short-course radiation
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital; Seoul National University Hospital; Samsung Medical Center; National Cancer Center, Korea
Recruiting - verified September 2011 - Condition: Colorectal Cancer
Interventions: Drug: Oxaliplatin; Drug: Folinic Acid; Drug: 5-fluoro-uracil; Drug: Irinotecan; Drug: Bevacizumab; Drug: Cetuximab
Sponsors: UNICANCER; UNICANCER
Recruiting - verified September 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Drug: gemcitabine, S-1; Drug: gemcitabine, S-1, radiotherapy
Sponsors: Osaka Medical Center for Cancer and Cardiovascular Diseases; Osaka Medical Center for Cancer and Cardiovascular Diseases
Enrolling by invitation - verified September 2011 - Condition: Hepatitis C
Intervention: Genetic: Interleukin 28B genotype
Sponsors: Henry Ford Health System; Henry Ford Health System
Recruiting - verified September 2011 - Condition: Colorectal Neoplasms
Intervention:
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified September 2011 - Conditions: Severe Crohn's Disease; Anxiety
Intervention:
Sponsors: Abbott; Abbott; Raffeiner GmbH
Recruiting - verified December 2011 - Condition: Liver Transplantation
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); University of Pennsylvania; Cornell University
Active, not recruiting - verified September 2011 - Conditions: Liver Failure; Kidney Failure
Intervention: Biological: Mesenchymal Stem Cells
Sponsors: University Hospital of Liege; University Hospital of Liege
Recruiting - verified February 2012 - Condition: Hepatitis C
Interventions: Drug: GS-9669 tablets; Drug: Placebo to Match GS-9669 tablet
Sponsors: Gilead Sciences; Gilead Sciences
Active, not recruiting - verified November 2011 - Conditions: Solid Tumor; Gastric Cancer
Intervention: Drug: E7050
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Recruiting - verified January 2012 - Condition: Inflammatory Bowel Disease
Interventions: Drug: Ferric oxide, saccharated; Drug: Glucose 5% solution
Sponsors: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives; Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Recruiting - verified April 2012 - Condition: Esophageal Cancer
Interventions: Other: Neoadjuvant chemoradiotherapy; Other: Adjuvant chemoradiotherapy
Sponsors: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Not yet recruiting - verified September 2011 - Condition: Crohns Disease
Intervention: Drug: ZP1848
Sponsors: MDS Pharma Services; MDS Pharma Services
Completed - verified September 2011 - Condition: Esophageal Varices Secondary to Cirrhosis of Liver
Interventions: Drug: Somatostatin; Procedure: endoscopic therapy
Sponsors: Chinese PLA General Hospital; Yunsheng Yang
Recruiting - verified August 2011 - Condition: Colorectal Cancer
Intervention: Procedure: Laparoscopic technique and thoracic epidural anesthesia
Sponsors: Complutense University; Complutense University; Hospital General Universitario Gregorio Marañon
Completed - verified August 2011 - Condition: Colorectal Cancer
Interventions: Dietary Supplement: Vitamin C; Dietary Supplement: Vitamin B6; Dietary Supplement: Folic acid; Dietary Supplement: Vitamin B6 plus folic acid
Sponsors: Taichung Veterans General Hospital; Taichung Veterans General Hospital
Active, not recruiting - verified August 2011 - Condition: Rectal Cancer Patients
Intervention: Other: Bevacizumab 5 mg/kg
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified August 2011 - Condition: Inflammatory Bowel Diseases
Interventions: Procedure: blood sample; Procedure: Blood sample - venous blood 10 ml.
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012 - Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: Akt inhibitor MK2206; Genetic: mutation analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Hemorrhoids
Intervention: Device: EnSeal Trio Tissue Sealing Device
Sponsors: Swedish Medical Center; Swedish Medical Center
Recruiting - verified January 2012 - Condition: Inflammatory Bowel Disease
Intervention: Behavioral: Multi-Convergent Therapy
Sponsors: Cardiff and Vale University Health Board; Cardiff and Vale University Health Board
Enrolling by invitation - verified August 2011 - Condition: Tumor
Intervention: Other: 18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified August 2011 - Conditions: Liver Failure; Liver Diseases; Liver Cirrhosis; Liver Neoplasms
Intervention: Drug: Everolimus
Sponsors: Azienda Ospedaliera di Padova; Azienda Ospedaliera di Padova
Recruiting - verified September 2011 - Condition: Acute Appendicitis
Interventions: Procedure: single incision laparoscopic appendectomy; Procedure: conventional laparoscopic appendectomy
Sponsors: Mansoura University; Mansoura University
Completed - verified August 2011 - Condition: CHOLELITHIASIS
Interventions: Procedure: Single-port cholecystectomy; Procedure: Four-port laparoscopic cholecystectomy
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012 - Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Secondary Malignant Neoplasm of Liver
Intervention: Other: magnetic resonance imaging (MRI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011 - Condition: Hepatic Impairment
Intervention: Drug: afq056
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced NeuropathyConditions: Neuropathy; Gastrointestinal Cancer
Intervention: Other: 12 Week Exercise Program
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; ONS Foundation
Recruiting - verified January 2012 - Conditions: Gastrointestinal Neoplasms; Urogenital Neoplasms
Intervention: Procedure: Medical Acupuncture
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; BC Cancer Foundation
Active, not recruiting - verified August 2011 - Condition: Rectal Cancer
Intervention: Biological: Panitumumab
Sponsors: National Center for Tumor Diseases, Heidelberg; National Center for Tumor Diseases, Heidelberg
Recruiting - verified April 2012 - Condition: Functional Dyspepsia
Interventions: Procedure: Traditional Medical Consultation; Procedure: Therapeutic Encounter
Sponsors: Faculdade de Medicina do ABC; Faculdade de Medicina do ABC; Feculdade de Medicina da Universidade de Sao Paulo - Brasil
Recruiting - verified October 2011 - Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012 - Conditions: Parkinson Disease; Dysphagia
Interventions: Other: Swallowing exercise; Other: Breathing Exercises; Other: Swallowing and breathing exercises
Sponsors: Federal University of Bahia; Federal University of Bahia
Not yet recruiting - verified August 2011 - Condition: Hepatitis B Virus (HBV) Associated Liver Disease.
Intervention: Biological: Hepatitis B Immune Globulin (Boca HBVIg)
Sponsors: Biotest Pharmaceuticals Corporation; Biotest Pharmaceuticals Corporation
Completed - verified August 2011 - Condition: Stomach Diseases
Intervention:
Sponsors: Anhui Medical University; Anhui Medical University; Technion, Israel Institute of Technology
Completed - verified December 2011 - Condition: Appendicitis
Intervention: Drug: metronidazole and cephalzolin
Sponsors: Monash University; Monash University; Monash Medical Centre
Not yet recruiting - verified August 2011 - Conditions: Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer
Interventions: Drug: FOLFOX6; Biological: EGFRBi armed ATC Infusions
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified September 2011 - Conditions: Malnourished; Stomach Neoplasms; Gastrointestinal Stromal Tumors
Interventions: Dietary Supplement: Ensure powder; Other: Standard care
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Abbott
Recruiting - verified August 2011 - Conditions: Alpha-1 Antitrypsin Deficiency; Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: Alpha-1 Foundation; Alpha-1 Foundation
Completed - verified September 2011 - Condition: Colon Cancer
Intervention: Procedure: Transversus Abdominis Plane block
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital
Recruiting - verified May 2011 - Condition: Non-alcoholic Fatty Liver Disease (NAFLD)
Intervention: Other: Physical exercise
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Recruiting - verified August 2011 - Conditions: Crohn's Disease; Ulcerative Colitis
Intervention:
Sponsors: University of Erlangen-Nürnberg Medical School; University of Erlangen-Nürnberg Medical School; Merck
Recruiting - verified August 2011 - Condition: Ulcerative Colitis
Interventions: Drug: Rectal tactolimus; Drug: Placebo
Sponsors: The University of Western Australia; The University of Western Australia; Mater Health Services' Adult Hospital, Brisbane, Qld; Concord Hospital; The Canberra Hospital; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified August 2011 - Condition: Colorectal Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: Placebo; Drug: bevacizumab [Avastin]; Drug: FOLFOX regimen; Drug: leucovorin; Drug: 5-FU
Sponsors: Genentech; Genentech; Sarah Cannon Research Institute
Recruiting - verified January 2012 - Condition: Irritable Bowel Syndrome
Interventions: Drug: Ayurvedic Herbs; Drug: Placebo tea
Sponsors: Universität Duisburg-Essen; Universität Duisburg-Essen
Recruiting - verified May 2011 - Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: FOLFIRI regimen; Drug: FOLFIRI-bevacizumab regimen; Drug: FOLFOX regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Federation Francophone de Cancerologie Digestive
Not yet recruiting - verified October 2011 - Conditions: Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity
Interventions: Biological: cetuximab; Biological: panitumumab; Drug: erlotinib hydrochloride; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Federation Francophone de Cancerologie Digestive
Recruiting - verified August 2011 - Condition: Non-alcoholic Fatty Liver Disease
Intervention:
Sponsors: Gulhane School of Medicine; Gulhane School of Medicine
Not yet recruiting - verified August 2011 - Conditions: Pseudopolyp; Inflammatory Bowel Disease
Intervention: Other: Endoscopic techniques
Sponsors: University of Miami; University of Miami; Olympus America
Recruiting - verified March 2012 - Condition: Esophageal Cancer
Intervention: Other: fluid optimisation
Sponsors: University Hospital, Linkoeping; University Hospital, Linkoeping
Recruiting - verified October 2011 - Condition: Colorectal Cancer
Intervention: Other: McCorkle Model Intervention
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Tampa General Hospital; University of South Florida; Yale University
Recruiting - verified March 2012 - Conditions: Malignant Neoplasm of Esophagus; Malignant Neoplasm of Stomach
Interventions: Drug: Oxaliplatin; Drug: Folinic Acid; Drug: 5-fluoro-uracil; Drug: panitumumab; Drug: AMG102
Sponsors: UNICANCER; UNICANCER
Recruiting - verified September 2011 - Conditions: Crohn´s Disease; Ulcerative Colitis
Intervention: Device: High-definition white light endoscopy and i-Scan
Sponsors: University of Erlangen-Nürnberg Medical School; University of Erlangen-Nürnberg Medical School
Recruiting - verified August 2011 - Conditions: Crohn´s Disease; Ulcerative Colitis
Intervention: Device: Endomicroscopy
Sponsors: University of Erlangen-Nürnberg Medical School; University of Erlangen-Nürnberg Medical School
Recruiting - verified August 2011 - Conditions: Gastrointestinal Neoplasms; Gastric Cancer
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic; Olympus
Active, not recruiting - verified August 2011 - Conditions: Breast Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer
Intervention: Behavioral: FOCUS-Web
Sponsors: University of Michigan; University of Michigan; National Cancer Institute (NCI); Wayne State University; Barbara Ann Karmanos Cancer Institute; Saint Joseph Mercy Health System
Completed - verified August 2011 - Condition: Colorectal Cancer
Interventions: Drug: Oxaliplatin; Drug: Folinic Acid; Drug: 5-fluoro-uracil; Drug: Irinotecan; Drug: Irinotecan; Drug: Bevacizumab; Drug: Cetuximab
Sponsors: UNICANCER; UNICANCER
Recruiting - verified September 2011 - Conditions: Healthy; Hepatic Impairment
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Favipiravir
Sponsors: FujiFilm Pharmaceuticals U.S.A., Inc.; FujiFilm Pharmaceuticals U.S.A., Inc.
Enrolling by invitation - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: GVAX Pancreas, Cyclophosphamide and CRS-207; Drug: GVAX Pancreas and Cyclophosphamide
Sponsors: Aduro BioTech, Inc.; Aduro BioTech, Inc.; Johns Hopkins University
Recruiting - verified May 2012 - Conditions: Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Amatuximab (MORab-009)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: DPX-Survivac; Drug: low dose cyclophosphamide (oral)
Sponsors: ImmunoVaccine Technologies, Inc.; ImmunoVaccine Technologies, Inc.
Recruiting - verified December 2011 - Condition: Colorectal Neoplasms
Interventions: Drug: Dendritic Cell Vaccine; Other: Supportive treatment
Sponsors: Fundacion Clinic per a la Recerca Biomédica; Fundacion Clinic per a la Recerca Biomédica
Recruiting - verified November 2011 - Condition: Hepatic Impairment
Intervention: Drug: RLX030A
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified March 2012 - Condition: End Stage Liver Disease
Intervention: Biological: Stem cell transplant
Sponsors: King Saud University; King Saud University
Not yet recruiting - verified May 2011 - A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic CholecystectomyCondition: Gallbladder Diseases
Intervention: Procedure: cholecystectomy
Sponsors: Mansoura University; Mansoura University
Recruiting - verified January 2011 - Condition: Pancreatic Cancer, Metastatic
Interventions: Drug: Gemcitabine, Erlotinib, OSI-906; Drug: Gemcitabine, Erlotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified May 2012 - Condition: Tumor of Exocrine Pancreas
Intervention: Procedure: Distal pancreatectomy with partial splenectomy
Sponsors: University of Missouri-Columbia; University of Missouri-Columbia
Not yet recruiting - verified August 2011 - Condition: Hepatic Impairment
Intervention: Drug: TR-701 FA
Sponsors: Trius Therapeutics, Inc.; Trius Therapeutics, Inc.
Recruiting - verified September 2011 - Condition: Digestive System Abnormalities
Intervention:
Sponsors: Goethe University; Goethe University
Recruiting - verified October 2011 - Condition: Dysphagia
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Institutes of Health Research (CIHR); Canadian Cancer Society
Recruiting - verified January 2012 - Condition: Dysphagia
Interventions: Other: Toronto Bedside Swallowing Screening Test (TOR-BSST©); Procedure: Videofluoroscopic Swallow Study
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2012 - Condition: Acute Appendicitis Without Peritonitis
Interventions: Drug: Ertapenem; Procedure: appendectomy
Sponsors: Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo
Recruiting - verified August 2011 - Condition: Colon Cancer Screening
Interventions: Behavioral: Information + Narratives + Support Group; Behavioral: Information Only
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Active, not recruiting - verified August 2011 - Condition: Pancreas Cancer
Interventions: Drug: gemcitabine; Drug: 5-fluorouracil
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Metastatic Pancreatic Cancer
Intervention: Drug: vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Oncovir, Inc.
Recruiting - verified April 2012 - Conditions: Gallbladder Disease; Biliary Colic; Gallstones
Intervention: Drug: Indocyanine green (ICG)
Sponsors: Intuitive Surgical; Intuitive Surgical; SS.Antonio e Biagio e Cesare Arrigo; University Hospital, Geneva
Recruiting - verified August 2011 - Condition: Parenteral Nutrition Associated Liver Disease in Infants
Intervention: Drug: Intravenous Lipid Emulsion Comprised of Fish Oil
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified August 2011 - Condition: Colorectal Carcinoma
Interventions: Drug: Panitumumab, Doxycycline/Placebo; Drug: Panitumumab
Sponsors: Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; ClinAssess - Gesellschaft für klinische Forschung mbH
Not yet recruiting - verified August 2011 - Condition: Metastatic Colorectal Cancer
Intervention: Other: Perfusion CT scan
Sponsors: University of Oxford; University of Oxford; Oxford University Hospitals NHS Trust; Oxfordshire Health Services Research Committee; University Hospitals, Leicester
Recruiting - verified August 2011 - Conditions: Gastric Cancer; Colon Nos Polypectomy Tubular Adenoma; Gastric Adenoma
Intervention: Drug: Menthol
Sponsors: Nihon Pharmaceutical Co., Ltd; Nihon Pharmaceutical Co., Ltd
Active, not recruiting - verified February 2012 - Conditions: Sphincter of Oddi Dysfunction; Abdominal Pain
Intervention:
Sponsors: Wisconsin Center for Advanced Research; Wisconsin Center for Advanced Research; Aurora Health Care
Terminated - verified August 2011 - Conditions: Peptic Ulcer Bleeding; Gastritis H Pylori; Atherothrombotic Diseases
Interventions: Drug: Rabeprazole; Drug: Famotidine
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified August 2011 - Conditions: Anus Neoplasms; Rectal Neoplasms; Urogenital Neoplasms
Interventions: Other: Aveeno cream; Other: Alkagin paste
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Dr. Te Vuong; Avario Healthcare
Recruiting - verified May 2012 - Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer ScreeningCondition: Colonic Neoplasms
Interventions: Behavioral: Control; Behavioral: Quantitative; Behavioral: Default
Sponsors: Indiana University; Indiana University
Recruiting - verified April 2012 - Condition: Gastric Cancer
Interventions: Drug: Menthol; Drug: Placebo
Sponsors: Nihon Pharmaceutical Co., Ltd; Nihon Pharmaceutical Co., Ltd
Active, not recruiting - verified February 2012 - Conditions: Abdominal Pain; Post-ERCP Acute Pancreatitis
Interventions: Device: Conventional 0.035 guidewire; Device: Olympus Visiglide 0.025 guidewire
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified August 2011 - Condition: Digestive System Disorders
Intervention: Drug: Ulimorelin
Sponsors: Norgine; Norgine
Recruiting - verified July 2011 - Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy VolunteersCondition: Digestive System Disorders
Interventions: Drug: Midazolam; Drug: Ulimorelin
Sponsors: Norgine; Norgine
Recruiting - verified July 2011 - Condition: Rectal Cancer
Interventions: Procedure: robot-assisted surgery; Procedure: Laparoscopic surgery
Sponsors: Kyungpook National University; Kyungpook National University
Recruiting - verified November 2011 - Condition: Rectal Cancer
Interventions: Drug: Placebo drug; Drug: Udenafil
Sponsors: Kyungpook National University; Kyungpook National University
Active, not recruiting - verified December 2011 - Condition: Gastric Cancer
Intervention: Drug: Capecitabine, Cisplatin
Sponsors: Epidemiological and Clinical Research Information Network; Epidemiological and Clinical Research Information Network
Recruiting - verified August 2011 - Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011 - Conditions: Metastatic or Recurrent Colorectal Cancer; Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan; Salvage Chemotherapy
Intervention: Drug: Gemcitabine and UFTE chemotherapy
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital; Seoul National University Hospital; SMG-SNU Boramae Medical Center; Yuhan Pharmaceutical Company; Jeil Pharmaceutical Company
Recruiting - verified July 2011 - Condition: Rectal Cancer
Intervention: Drug: nitroglycerin
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Department of Veterans Affairs
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Capecitabine; Drug: Hydroxychloroquine; Radiation: Proton Radiation Therapy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified December 2011 - Condition: Pancreatic Neoplasms
Interventions: Drug: oxaliplatin; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Other: laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method; Other: pharmacological study; Drug: PF-04136309
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ulcerative Colitis; Crohn's Disease
Intervention:
Sponsors: Dallas VA Medical Center; Dallas VA Medical Center; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified February 2011 - Conditions: Prevention; Rehabilitation
Interventions: Procedure: Videofluroscopic swallow study (VFSS); Procedure: cervical spine isometric exercises; Procedure: Fiberoptic endoscopic esophageal study (FEES)
Sponsors: University of Ioannina; University of Ioannina
Recruiting - verified August 2011 - Conditions: Liver Diseases, Alcoholic; Alcoholism; HIV; Hepatitis C
Interventions: Other: Integrated Stepped Care (ISC); Other: Treatment as Usual
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Department of Veterans Affairs
Not yet recruiting - verified August 2011 - Conditions: Hepatitis C; Renal Cell Carcinoma; Colorectal Cancer
Intervention: Other: Hepatitis C testing
Sponsors: Henry Ford Health System; Henry Ford Health System; Schering-Plough
Recruiting - verified June 2011 - Condition: Pancreatic Neoplasms
Intervention: Dietary Supplement: Ketogenic diet
Sponsors: University of Iowa; University of Iowa; National Institutes of Health (NIH); Nutricia North America; The Holden Comprehensive Cancer Center
Recruiting - verified August 2011 - Condition: Gastric Cancer
Interventions: Drug: SP; Drug: XP
Sponsors: Epidemiological and Clinical Research Information Network; Epidemiological and Clinical Research Information Network
Not yet recruiting - verified July 2011 - Conditions: Gastroesophageal Reflux Disease; Eosinophilic Esophagitis
Intervention: Drug: Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
Sponsors: Dallas VA Medical Center; Dallas VA Medical Center; TAP Pharmaceutical Products Inc.
Terminated - verified October 2007 - Conditions: Blood Pressure; Colorectal Cancer Screening
Interventions: Behavioral: Motivational Interviewing; Behavioral: Patient Navigation
Sponsors: New York University School of Medicine; New York University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2011 - Conditions: Esophageal Cancer; Adenocarcinoma, Esophageal; Squamous Cell Carcinoma, Esophageal; Carcinoma, Gastroesophageal Junction
Interventions: Drug: carboplatin and paclitaxel; Other: Carboplatin paclitaxel plus concurrent radiotherapy
Sponsors: Capital District Health Authority, Canada; Gordon Buduhan; Capital Health, Canada
Recruiting - verified January 2012 - Conditions: Colorectal Cancer; Metastasis
Intervention: Biological: Bevacizumab + blood samples
Sponsors: Centre Leon Berard; Centre Leon Berard; UMR-S Inserm 1036
Recruiting - verified October 2011 - Condition: Esophageal Squamous Cell Carcinoma
Interventions: Biological: Nimotuzumab; Radiation: Radiation therapy; Radiation: radiation therapy; Drug: chemotherapy; Drug: chemotherapy
Sponsors: Fudan University; Fudan University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China; SHANGHAI RENJI HOSPITAL; Shanghai First People's Hospital
Recruiting - verified November 2010 - Conditions: Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Multiple Myeloma
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Active, not recruiting - verified January 2012 - Conditions: Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage I Colon Cancer; Stage I Rectal Cancer
Interventions: Dietary Supplement: cholecalciferol; Procedure: biopsy; Genetic: protein expression analysis; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Genetic: reverse transcriptase-polymerase chain reaction
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Adenocarcinoma of Colon Recurrent
Interventions: Dietary Supplement: Eviendep (CM&D Pharma Limited, UK); Dietary Supplement: Maltodextrins
Sponsors: CM&D Pharma Limited; CM&D Pharma Limited
Completed - verified July 2011 - Conditions: Cancer; Liver Cancer; Hepatocellular Carcinoma
Interventions: Drug: PI-88; Other: Placebo
Sponsors: Medigen Biotechnology Corporation; Medigen Biotechnology Corporation
Recruiting - verified February 2012 - Condition: Advanced Gastric Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Not yet recruiting - verified July 2011 - Conditions: Hepato/Renal Fibrocystic Disease; Autosomal Recessive Polycystic Kidney Disease; Joubert Syndrome; Bardet Biedl Syndrome; Meckel-Gruber Syndrome; Congenital Hepatic Fibrosis; Caroli Syndrome; Oro-Facial-Digital Syndrome Type I; Nephronophithisis; Glomerulocystic Kidney Disease
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Condition: Gastric Cancer
Interventions: Drug: mistletoe extract; Drug: doxifluridine
Sponsors: Abnoba Gmbh; Abnoba Gmbh
Completed - verified July 2011 - Conditions: Adenocarcinoma of the Pancreas; Normal Pancreatic Exocrine Function
Interventions: Other: Timing of start treatment with pancreatic enzymes; Other: Timing of start treatment with pancreatic enzymes
Sponsors: Foundation for Liver Research; Foundation for Liver Research
Active, not recruiting - verified February 2012 - Condition: Gastroesophageal Reflux Disease
Intervention: Drug: AGSPT201 Tab contains S-pantoprazole
Sponsors: Ahn-Gook Pharmaceuticals Co.,Ltd; Ahn-Gook Pharmaceuticals Co.,Ltd
Completed - verified September 2011 - Conditions: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes
Intervention: Drug: Liraglutide-metformin vs insulin-metformin
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Diabete Quebec; Radiological Society of North America Research and Education Foundation; Canadian Heads of Academic Radiology-GE Healthcare Development Award
Recruiting - verified July 2011 - Conditions: Non-small Cell Lung Cancer; Small Cell Lung Cancer; Mesothelioma; Esophageal Cancer; Gastric Cancer; Liver Cancer; Biliary Cancer
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Conditions: Gastric Cancer; Esophageal Cancer; Pancreatic Cancer; Liver Cancer; Biliary Cancer
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Active, not recruiting - verified July 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Barrett's Esophagus
Intervention: Device: optical frequency domain imaging (OFDI) system
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Carcinoma; Carcinoma, Renal Cell; Neuroendocrine Tumors; Carcinoid Tumor; Pancreatic Islet Cell Tumors
Intervention: Other: Blood sampling by vena punction.
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen
Completed - verified May 2012 - Conditions: Gastroesophageal Reflux Disease; GERD; Reflux Esophagitis
Intervention: Drug: esomeprazole 20 mg
Sponsors: AstraZeneca; AstraZeneca; Parexel
Not yet recruiting - verified July 2011 - Condition: Glucose Metabolism Disorders
Intervention:
Sponsors: Hospital Universitario Dr. Jose E. Gonzalez; Hospital Universitario Dr. Jose E. Gonzalez
Active, not recruiting - verified November 2007 - Conditions: Enteropathy-Associated T-Cell Lymphoma; Anaplastic Large-Cell Lymphoma; Cutaneous T-Cell Lymphoma; Primary Cutaneous Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox
Sponsors: TSD Japan Inc.; TSD Japan Inc.; Eisai Co., Ltd.
Recruiting - verified July 2011 - Condition: Low Rectal Adenocarcinoma
Intervention: Procedure: Colonic reservoir
Sponsors: Hospital Universitari de Bellvitge; Hospital Universitari de Bellvitge
Completed - verified November 2000 - Condition: Pancreatic Cancer
Intervention: Drug: Oxaliplatin, irinotecan, 5-FU & leucovorin
Sponsors: Odense University Hospital; Odense University Hospital
Not yet recruiting - verified June 2011 - Conditions: Metastatic or Recurrent Gastric Adenocarcinoma; Her-2 Positive Gastric Cancer
Intervention: Drug: Herceptin+XELOX
Sponsors: Asan Medical Center; Asan Medical Center; Hoffmann-La Roche
Recruiting - verified December 2011 - Condition: Advanced Gastric Cancer
Intervention: Drug: Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Sponsors: Asan Medical Center; Asan Medical Center; Roche Pharma AG
Recruiting - verified November 2011 - Conditions: Advanced Stomach Cancer; Peritoneal Seeding
Intervention: Drug: DXP+AVASTIN
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified February 2012 - Condition: Celiac Disease
Interventions: Drug: Larazotide Acetate 0.5 mg; Drug: Larazotide Acetate 1 mg; Drug: Larazotide Acetate 2 mg; Drug: placebo
Sponsors: Alba Therapeutics; Alba Therapeutics; Teva Pharmaceuticals USA
Recruiting - verified July 2011 - Condition: Rectal Cancer
Intervention: Other: CCRT
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified September 2011 - Condition: Esophageal Squamous Cell Carcinoma
Interventions: Radiation: Elective nodal irradiation (ENI); Other: Adjuvant chemotherapy only
Sponsors: Fudan University; Fudan University; The First Affiliated Hospital of Soochow University; NANTONG TUMOR HOSPITAL; Jiangsu Cancer Institute & Hospital; AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY; Zhejiang Cancer Hospital; Wenzhou Medical College; Zhejiang University; Anhui Medical University; Anhui Provincial Hospital; Fujian Cancer Hospital; Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China; SHANGHAI RENJI HOSPITAL
Recruiting - verified March 2011 - Conditions: Colorectal Carcinoma; CRC
Interventions: Biological: JX-594; Drug: Irinotecan
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Transgene
Recruiting - verified January 2012 - Condition: Functional Gastrointestinal Disorders
Interventions: Drug: Glucomannan; Drug: placebo
Sponsors: Medical University of Warsaw; Medical University of Warsaw
Recruiting - verified December 2011 - Conditions: Liver Failure; Liver Failure, Acute; Liver Diseases; Carcinoma, Hepatocellular; Liver Neoplasms
Intervention: Drug: N-acetylcystein
Sponsors: Azienda Ospedaliera di Padova; Azienda Ospedaliera di Padova
Completed - verified September 2011 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: FOLFOXIRI plus bevacizumab
Sponsors: Azienda Ospedaliero, Universitaria Pisana; Azienda Ospedaliero, Universitaria Pisana
Completed - verified September 2011 - Condition: Hepatic Impairment
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pancreatic Neoplasm
Interventions: Procedure: Procore Biopsy; Procedure: FNA
Sponsors: University of Alabama at Birmingham; Shyam Varadarajulu
Completed - verified December 2011 - Condition: Primary Biliary Cirrhosis
Interventions: Drug: ustekinumab (double-blind); Drug: ustekinumab (double-blind); Drug: ustekinumab (open-label); Drug: ustekinumab (double-blind); Drug: Placebo
Sponsors: Centocor Research & Development, Inc.; Centocor Research & Development, Inc.
Recruiting - verified May 2012 - Conditions: Crohn's Disease; Intestinal Tuberculosis
Intervention:
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified September 2011 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: rabeprazole; Drug: standard dose rabeprazole
Sponsors: Inje University; Inje University
Withdrawn - verified January 2012 - Conditions: Esophageal Cancer; Adenocarcinoma
Interventions: Other: serum and tissue mesothelin; Other: serum and tissue mesothelin; Other: serum and tissue mesothelin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Colon Cancer
Interventions: Procedure: Inspection with Narrow-Band Imaging(NBI); Procedure: Standard White Light
Sponsors: Indiana University; Indiana University; Olympus
Recruiting - verified April 2012 - Conditions: Colorectal Cancer; Breast Cancer; Cervical Cancer
Interventions: Behavioral: IVR only; Behavioral: IVR+PCC
Sponsors: Harvard School of Public Health; Harvard School of Public Health; National Cancer Institute (NCI)
Active, not recruiting - verified July 2011 - Conditions: Diabetes Mellitus Type 1 and 2; Diabetes Mellitus Complications; Gastroparesis; Gastrointestinal Motility Disorder
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Esophageal Squamous Cell Carcinoma
Interventions: Radiation: enlarge irradiation volume; Radiation: Small volume radiation; Drug: cisplatin; Drug: fluorouracil
Sponsors: Fudan University; Fudan University; The First Affiliated Hospital of Soochow University; NANTONG TUMOR HOSPITAL; Jiangsu Cancer Institute & Hospital; AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY; Zhejiang Cancer Hospital; Wenzhou Medical College; Zhejiang University; Anhui Medical University; Anhui Provincial Hospital; Fujian Cancer Hospital; Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China; SHANGHAI RENJI HOSPITAL
Recruiting - verified March 2011 - Condition: Drug-Induced Liver Injury
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Sponsors: Bayer; Bayer; RTI Health Solutions
Completed - verified September 2011 - Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012 - Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: Pazopanib
Sponsors: Stanford University; Kristen Ganjoo; GlaxoSmithKline
Recruiting - verified December 2011 - Conditions: Prostate Cancer; Pancreatic Cancer; Melanoma; Renal Cell Carcinoma; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Bladder Cancer; Non-small Cell Lung Cancer; Glioblastoma
Intervention: Biological: MGA271
Sponsors: MacroGenics; MacroGenics
Recruiting - verified December 2011 - Condition: Pancreatic Fistula
Interventions: Drug: Intraarterial application of Octreotide; Drug: sterile NaCl (sodium chloride) 0,9% solution
Sponsors: St. Josef Hospital Bochum; St. Josef Hospital Bochum
Completed - verified March 2012 - Conditions: Barrett Esophagus; Esophageal Adenocarcinoma
Intervention: Drug: GI heptapeptide
Sponsors: University of Michigan; University of Michigan
Recruiting - verified January 2012 - Conditions: Underlying Liver Disease; Hepatitis; Fibrosis of Liver; Cirrhosis With Suspicion of Liver Cancer; Lesion on a Prior Ultrasound, CT or Outside MRI
Intervention:
Sponsors: University of Nebraska; University of Nebraska
Recruiting - verified August 2011 - Conditions: Pancreatic Cancer; Chronic Pancreatitis; Type II Diabetes; Pancreatic Cysts; Control
Intervention: Procedure: Blood Draw
Sponsors: University of Michigan; University of Michigan
Recruiting - verified January 2012 - Conditions: Inflammatory Bowel Disease; Anaemia
Intervention: Drug: Monofer
Sponsors: Pharmacosmos A/S; Pharmacosmos A/S
Recruiting - verified August 2011 - Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux LaryngitisConditions: Gastroesophageal Reflux Disease (GERD); Chronic Laryngitis
Interventions: Drug: omeprazole; Behavioral: dietary and lifestyle changes
Sponsors: Faculdade de Ciências Médicas da Santa Casa de São Paulo; Faculdade de Ciências Médicas da Santa Casa de São Paulo
Completed - verified March 2012 - Condition: Crohn's Disease
Interventions: Drug: TU-100; Drug: Matching Placebo
Sponsors: Tsumura USA; Tsumura USA; INC Research
Recruiting - verified May 2012 - Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: Targeted Therapy Tailored Treatment; Drug: Standard Chemotherapy
Sponsors: Grupo Hospital de Madrid; Sofia Perea, Director Clinical Trials Unit.
Recruiting - verified March 2012 - Conditions: Crohn Disease; Fistula; Anoperineal Fistula; Anal Fistula
Interventions: Procedure: All types of surgery procedures; Procedure: Simple seton drain removal
Sponsors: French Society of Coloproctology; French Society of Coloproctology
Not yet recruiting - verified July 2011 - Condition: Chronic Liver Disease
Interventions: Drug: NISSEL; Drug: PENNEL
Sponsors: PharmaKing; PharmaKing
Completed - verified July 2011 - Condition: Chronic Liver Disease
Interventions: Drug: PENNEL capsule; Drug: Placebo
Sponsors: PharmaKing; PharmaKing
Completed - verified July 2011 - Condition: Biliary Carcinoma
Interventions: Drug: Panitumumab plus GEMOX chemotherapy; Drug: GEMOX chemotherapy
Sponsors: Fondazione del Piemonte per l'Oncologia; Prof. Massimo Aglietta
Recruiting - verified February 2012 - Condition: Pancreatic Cancer
Intervention: Drug: gemcitabine and cisplatin
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Completed - verified July 2011 - Condition: Pancreatic Cancer
Intervention: Drug: gemcitabine, cisplatin, capecitabine
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Completed - verified July 2011 - Condition: Liver Cancer
Intervention: Device: Electrosensing antibody probing system (e- Ab sensor)
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified May 2011 - Condition: Digestive System Diseases
Intervention: Behavioral: endoscopic submucosal dissection
Sponsors: Chinese PLA General Hospital; Chinese PLA General Hospital
Recruiting - verified May 2011 - Conditions: Colon Cancer; Benign Colon Diseases
Intervention: Procedure: Elective colon resection
Sponsors: Ostfold Hospital Trust; Ostfold Hospital Trust
Active, not recruiting - verified August 2011 - Conditions: Crohn's Disease; Ileitis; Ileo-colonic and Colonic Crohn's Disease; Granulomatous Colitis; Regional Enteritis
Interventions: Procedure: lumbar puncture; Drug: lumbar puncture
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Renal Cell Carcinoma; Soft Tissue Sarcoma; Glioblastoma; Ovarian Cancer; Cervical Cancer; Breast Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Gastrointestinal Cancer
Intervention: Drug: Pazopanib
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; GlaxoSmithKline; Cambridge Experimental Cancer Medicine Centre
Recruiting - verified June 2011 - Conditions: Breast Cancer; Colon Cancer; Pancreatic Cancer; Sarcoma; Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide; Drug: CT-011
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Withdrawn - verified October 2011 - Conditions: Carcinoma, Hepatocellular; Cirrhosis
Intervention: Procedure: Liver transplantation
Sponsors: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; AISF (Associazione Italiana per lo Studio del Fegato); CNT (Centro Nazionale Trapianti); NITp (Nord Italia Transplant project); OCST (Organizzazione Centro Sud Trapianti); AIRC (Associazione Italiana per la Ricerca sul Cancro); Ministero della Salute, Italy; Basilicata Region
Recruiting - verified June 2011 - Condition: Pancreatic Cancer
Interventions: Drug: SOM 230 LAR; Drug: Gemcitabine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Chronic Liver Disease
Interventions: Drug: G-CSF+EPO; Drug: Placebo
Sponsors: Institute of Liver and Biliary Sciences, India; Institute of Liver and Biliary Sciences, India
Recruiting - verified June 2011 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: E3710; Drug: E3710
Sponsors: Eisai Inc.; Eisai Co., Ltd.
Completed - verified March 2012 - Conditions: Reflux; Gastroesophageal Reflux Disease (GERD)
Intervention:
Sponsors: Duke University; Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Sore Throat; Dysphagia; Dysphonia
Interventions: Device: Standard inflation of LMA cuff; Device: Pressure check with syringe recoil; Device: Pressure check by pressure transducer
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified February 2012 - Condition: Colorectal Cancer Screening
Intervention: Other: Outreach by a preventive care care manager
Sponsors: Northwestern University; Northwestern University
Completed - verified July 2011 - Conditions: Barrett's Esophagus; Intraepithelial Neoplasia
Intervention: Drug: proflavine
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.; William Marsh Rice University
Recruiting - verified September 2011 - Conditions: GERD; Barrett's Esophagus
Interventions: Drug: Fluorescein; Drug: Proflavine hemisulfate
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.
Recruiting - verified June 2011 - Condition: Deglutition Disorders
Intervention: Drug: Piperine
Sponsors: Hospital de Mataró; Hospital de Mataró
Recruiting - verified February 2012 - Conditions: Breast Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab; Biological: trastuzumab
Sponsors: Areva Med LLC; Areva Med LLC
Recruiting - verified January 2012 - Conditions: Fracture of Surgical Neck of Humerus; Colonic Tumor; Stage IIIB Ovarian Carcinoma; Neoplasm of Head of Pancreas
Intervention:
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany
Completed - verified September 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Everolimus; Drug: Everolimus
Sponsors: Herlev Hospital; Herlev Hospital; Odense University Hospital; Aalborg Hospital
Completed - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Recombinant anti-tumor and anti-virus protein for injection; Drug: Recombinant anti-tumor and anti-virus protein for injection; Other: Saline Injection
Sponsors: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; Beijing Genova Biotech Company, Ltd.
Recruiting - verified January 2012 - Condition: Colorectal Cancer
Interventions: Behavioral: Health counselling by nurse navigator; Behavioral: Usual primary care counselling
Sponsors: Cancer Care Ontario; Cancer Care Ontario; Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2012 - Conditions: Hepatocellular Carinoma; Liver Cancer; HCC
Interventions: Biological: JX-594 recombinant vaccina GM-CSF; Other: Best Supportive Care
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics
Recruiting - verified November 2011 - Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Interventions: Procedure: EUS-guided FNA performed with on-site Cytopathologist; Procedure: EUS-guided FNA performed without on-site Cytopathologist
Sponsors: Washington University School of Medicine; Washington University School of Medicine; University of Colorado, Denver; Kansas City Veteran Affairs Medical Center
Enrolling by invitation - verified June 2011 - Condition: Acute on Chronic Hepatic Failure
Interventions: Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO); Drug: Placebo
Sponsors: Institute of Liver and Biliary Sciences, India; Institute of Liver and Biliary Sciences, India
Recruiting - verified October 2011 - Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: FOLFIRI-bevacizumab regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Eosinophilic Gastrointestinal Disorders (EGID); Eosinophilic Esophagitis; Eosinophils
Intervention:
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2011 - Conditions: Post Infective IBS-D; Irritable Bowel Syndrome With Diarrhea
Intervention: Drug: Mesalamine
Sponsors: University of Utah; University of Utah; Shire Human Genetic Therapies, Inc.
Recruiting - verified August 2011 - Condition: Gastric Cancer
Intervention: Drug: Cetuximab and Chemotherapy (cisplatin + TS-1)
Sponsors: Merck KGaA; Merck KGaA
Active, not recruiting - verified January 2012 - Condition: Colorectal Cancer Metastatic
Intervention: Drug: Cetuximab
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus; Merck KGaA
Not yet recruiting - verified June 2011 - Conditions: Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors
Intervention: Drug: TH-302
Sponsors: Threshold Pharmaceuticals; Threshold Pharmaceuticals
Recruiting - verified July 2011 - Conditions: Chronic Obstructive Pulmonary Disease; Alpha-1-antitrypsin-deficiency
Intervention: Procedure: exercise training
Sponsors: Klinikum Berchtesgadener Land der Schön-Kliniken; Klinikum Berchtesgadener Land der Schön-Kliniken; Grifols Therapeutics Inc.; Alpha-1 Foundation
Recruiting - verified November 2011 - Comparison of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil and a Nitinol Guide WireCondition: Other Specified Diseases of Biliary Tract
Intervention: Device: Guidewire
Sponsors: Johann Wolfgang Goethe University Hospitals; Johann Wolfgang Goethe University Hospitals
Recruiting - verified June 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: GS-5885, GS-9451, PEG , RBV; Drug: PEG, RBV
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified February 2012 - Conditions: Pancreatic Cancer; Pancreatic Cystic Lesions; Chronic Pancreatitis; Pancreatic Neuroendocrine Tumors; Pancreatic Pseudocysts
Interventions: Procedure: Stapling closure of the pancreatic stump; Procedure: Roux-en-Y anastomosis of the pancreatic stump
Sponsors: Wakayama Medical University; Wakayama Medical University; Osaka University; Nara Medical University; Kyoto Prefectural University of Medicine; Kansai Rosai Hospital
Recruiting - verified June 2011 - Condition: Carcinoma, Colorectal
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Samsung Medical Center
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Skin Toxicities
Intervention:
Sponsors: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology; Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Recruiting - verified June 2011 - Conditions: Gastric Cancer; Chemoradiation
Intervention:
Sponsors: Kagawa University; Kagawa University
Completed - verified October 2005 - Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Intervention: Drug: panitumumab + docetaxel + cisplatino
Sponsors: Grupo Gallego de Investigaciones Oncologicas; Grupo Gallego de Investigaciones Oncologicas; Amgen; Trial Form Support S.L.
Recruiting - verified April 2011 - Conditions: Complex Perianal Fistula; Crohn Disease
Interventions: Drug: Expanded autologous adipose-derived adult stem cells (eASCs); Drug: Placebo
Sponsors: Cellerix; Cellerix
Terminated - verified June 2011 - Condition: Colon Polyp
Interventions: Procedure: Water infusion in lieu of air insufflation; Procedure: Air method
Sponsors: VA Northern California Health Care System; VA Northern California Health Care System
Recruiting - verified July 2011 - Condition: Barrett's Esophagus
Intervention: Drug: Proflavine Hemisulfate
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.; Mount Sinai School of Medicine
Completed - verified October 2011 - Conditions: Colon Cancer; Breast Cancer; Trauma; Inflammatory Bowel Disease; Hernia
Intervention:
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified July 2011 - Condition: Wilson's Disease
Intervention: Genetic: allogeneic mesenchymal stem cell transplantation
Sponsors: Gulhane Military Medical Academy; Murat Kantarcioglu; Gulhane Military Medical Academy
Recruiting - verified March 2012 - Condition: Colorectal Neoplasms
Intervention: Procedure: UPD guidance
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified September 2011 - Conditions: Pancreatic Cancer; Adenocarcinoma; Pancreatic Neoplasms
Intervention: Drug: FOLFIRINOX, IPI-926
Sponsors: University of California, San Francisco; University of California, San Francisco; Infinity Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Acute Appendicitis
Intervention: Other: CT scanning
Sponsors: University of Aarhus; University of Aarhus; Herning Hospital
Active, not recruiting - verified June 2011 - Conditions: Gastritis; Peptic Ulcer; Peptic Ulcer Perforation; Stomach Ulcer
Intervention: Other: Urea Breath Test (UBT) for H. pylori infection
Sponsors: George Washington University; George Washington University
Recruiting - verified June 2011 - Condition: Colorectal Cancer
Interventions: Drug: FOLFIRI regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: liposome-encapsulated irinotecan hydrochloride PEP02; Genetic: polymorphism analysis; Other: pharmacogenomic studies; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting - verified June 2011 - Condition: Rectal Cancer
Interventions: Drug: Sorafenib; Drug: 5-Fluorouracil (5-FU); Radiation: Radiation
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting - verified April 2012 - Conditions: Alpha-1-antitrypsin Deficiency; Liver Cirrhosis
Interventions: Drug: Drug-Carbamazepine (Tegretol XR); Drug: Carbamazepine (Tegretol XR) Placebo
Sponsors: University of Pittsburgh; University of Pittsburgh; Novartis; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified January 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Gilead Sciences; Gilead Sciences; Cystic Fibrosis Foundation
Active, not recruiting - verified December 2011 - Condition: Colorectal Cancer
Intervention: Drug: Pentamidine (OCZ103-OS), mFOLFOX6 or FOLFIRI
Sponsors: Oncozyme Pharma Inc.; Oncozyme Pharma Inc.
Recruiting - verified October 2011 - Conditions: Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Sarcoma; Gynecologic Cancer
Interventions: Drug: Doxorubicin; Drug: Sildenafil
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: TACE-DEB; Drug: 90Y-RE
Sponsors: University Hospital, Ghent; University Hospital, Ghent
Recruiting - verified March 2012 - Conditions: HIV Enteropathy; Diarrhea With HIV
Intervention: Drug: Crofelemer
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Active, not recruiting - verified October 2011 - Condition: Colon Cancer, Rectal Cancer
Interventions: Drug: Fentanyl; Drug: Dexmedetomidine
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Pharmbio Korea Co., Ltd.
Completed - verified March 2012 - Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Dietary Supplement: Soy Dietary Fiber; Dietary Supplement: Rice powder
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Not yet recruiting - verified June 2011 - Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine plus nab-paclitaxel
Sponsors: Grupo Hospital de Madrid; Grupo Hospital de Madrid
Recruiting - verified September 2011 - Condition: Functional Dyspepsia
Intervention: Drug: Acthrel
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City
Not yet recruiting - verified June 2011 - Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Lung Cancer; Cervical Cancer; Breast Cancer; Colorectal Cancer
Intervention: Behavioral: Lay health advisor interactions
Sponsors: University of Kentucky; University of Kentucky; National Center on Minority Health and Health Disparities (NCMHD)
Enrolling by invitation - verified June 2011 - Conditions: Breast Cancer; Colorectal Cancer; Cervical Cancer
Intervention: Other: TopCare: Use of provider knowledge vs. automated system
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Active, not recruiting - verified June 2011 - Condition: Colorectal Cancer
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Active, not recruiting - verified June 2011 - Conditions: Barrett's Esophagus; Intestinal Metaplasia; Gastroesophageal Reflux Disease (GERD)
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; American Society for Gastrointestinal Endoscopy
Recruiting - verified May 2012 - Conditions: Barrett's Esophagus; Gastroesophageal Reflux Disease (GERD); Intestinal Metaplasia
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Esophageal Cancer
Interventions: Drug: Paclitaxel with Cisplatin; Drug: Arm B
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified June 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885 tablet; Drug: GS-9451 tablet; Biological: peginterferon alfa-2a; Drug: ribavirin tablet
Sponsors: Gilead Sciences; Gilead Sciences
Active, not recruiting - verified December 2011 - Conditions: Melena; Hematemesis; Peptic Ulcer Hemorrhage; Variceal Hemorrhage
Intervention: Device: Video capsule endoscopy (Pillcam Eso2)
Sponsors: George Washington University; George Washington University; Given Imaging Ltd.
Recruiting - verified June 2011 - Conditions: Malignant Solid Tumour; Breast Cancer; Malignant Tumor of Colon; GIST; Ovarian Cancer
Intervention: Biological: HER-2 vaccine
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified February 2012 - Conditions: Breast Cancer; Ovarian Cancer; Colon Cancer; Thrombophilia
Intervention:
Sponsors: The Moses H. Cone Memorial Hospital; The Moses H. Cone Memorial Hospital; Duke University; University of North Carolina, Greensboro
Enrolling by invitation - verified June 2011 - Conditions: Colonic Polyp; Colon Cancer
Intervention: Other: Sample of polyp
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic CancerCondition: Pancreatic Neoplasms
Interventions: Radiation: neoadjuvant short course IMRT; Radiation: IORT
Sponsors: University Hospital Heidelberg; University Hospital Heidelberg; German Cancer Research Center
Not yet recruiting - verified June 2011 - Conditions: Neoplasms; Neoplasm Metastasis; Pancreatic Cancer
Interventions: Drug: LY2157299; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Liver Disease
Intervention: Drug: conivaptan hydrochloride
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012 - Condition: Liver Cirrhosis
Intervention: Procedure: Liver vein catheter
Sponsors: University of Aarhus; University of Aarhus
Recruiting - verified June 2011 - Conditions: Prostate Cancer (Post Prostatectomy); Anal Cancer; Nasopharyngeal Cancer; Intermediate Risk Prostate Cancer
Intervention: Other: Non-Interventional Study
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified June 2011 - Condition: Rectal Cancer
Intervention: Other: Ultrasonic Elastography
Sponsors: Vejle Hospital; Vejle Hospital
Active, not recruiting - verified May 2012 - Condition: Rectal Carcinoma
Interventions: Drug: Lanreotide Autogel 120mg; Drug: Placebo
Sponsors: University Hospital, Ghent; University Hospital, Ghent; Ipsen
Recruiting - verified March 2012 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease
Interventions: Drug: Placebo; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Enrolling by invitation - verified May 2012 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2012 - Condition: Crohn's Disease
Interventions: Dietary Supplement: Vitamin D3; Other: Placebo
Sponsors: University of Dublin, Trinity College; University of Dublin, Trinity College; Irish Research Council for Science, Engineering and Technology
Not yet recruiting - verified June 2011 - Conditions: Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity
Interventions: Other: Low-fat diet; Other: Low-carbohydrate diet
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Active, not recruiting - verified April 2012 - Condition: Pancreas Cancer
Intervention: Drug: Secretin Synthetic Human (RG1068)
Sponsors: University Hospital Case Medical Center; University Hospital Case Medical Center; Repligen Corporation
Recruiting - verified June 2011 - Conditions: Peritoneal Carcinomatosis; Gastric Cancer
Interventions: Drug: Neo-adjuvant chemotherapy; Procedure: Cytoreduction + hyperthermic intraperitoneal chemotherapy; Drug: Early peritoneal chemotherapy
Sponsors: Uppsala University; Uppsala University
Completed - verified May 2011 - Condition: Pancreatic Adenocarcinoma
Intervention: Device: NanoKnife Low Energy Direct Current (LEDC) System Ablation
Sponsors: Angiodynamics, Inc.; Angiodynamics, Inc.
Active, not recruiting - verified March 2012 - Conditions: Pancreatic Disease; Pancreatic Neoplasms
Interventions: Procedure: Drain removal at D4; Procedure: Standard drain removal
Sponsors: Centre Hospitalier Universitaire, Amiens; Centre Hospitalier Universitaire, Amiens
Recruiting - verified December 2011 - Condition: Cholestasis
Interventions: Drug: Intralipid/Liposyn; Drug: Intralipid/Liposyn
Sponsors: University of California, Los Angeles; University of California, Los Angeles; St. Louis University
Recruiting - verified June 2011 - Condition: HIV Disease
Interventions: Biological: alpha-1-Proteinase Inhibitor; Biological: alpha-1-Proteinase Inhibitor; Biological: alpha-1-Proteinase Inhibitor; Biological: alpha-1-Proteinase Inhibitor
Sponsors: Cabrini Medical Centre; Cabrini Medical Centre; CSL Behring
Completed - verified December 2006 - Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: Placebo; Drug: Oltipraz
Sponsors: PharmaKing; PharmaKing
Recruiting - verified June 2011 - Conditions: Rotavirus Diarrhea; Polio Plasma Neutralizing Antibody; Tropical Enteropathy
Interventions: Biological: IPV; Biological: Rotarix
Sponsors: University of Vermont; University of Vermont; Bill and Melinda Gates Foundation; University of Virginia; International Centre for Diarrhoeal Disease Research, Bangladesh; Washington University School of Medicine; Stanford University; Centers for Disease Control and Prevention
Recruiting - verified May 2011 - Condition: Dysphagia
Interventions: Behavioral: Tongue Pressure Profile Training; Behavioral: Tongue-Pressure Strength-and-Accuracy Training
Sponsors: Toronto Rehabilitation Institute; Toronto Rehabilitation Institute
Not yet recruiting - verified June 2011 - Conditions: Colorectal Cancer; Colorectal Adenocarcinoma
Interventions: Drug: Brivanib; Drug: Irinotecan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012 - Conditions: Uterine Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Cervical Cancer; Vulvar Cancer
Intervention: Other: Survey
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified June 2011 - Conditions: Malignant Dysphagia; Esophageal Cancer
Interventions: Radiation: Brachytherapy; Procedure: Stent insertion
Sponsors: McGill University Health Center; McGill University Health Center
Not yet recruiting - verified June 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012 - Condition: Gastric Cancer
Intervention:
Sponsors: Shandong University; Shandong University
Completed - verified December 2011 - Condition: Esophageal Cancer
Interventions: Drug: Endostar; Radiation: Radiotherapy
Sponsors: Jiangsu Simcere Pharmaceutical R&D Co. Ltd.; Jiangsu Simcere Pharmaceutical R&D Co. Ltd.; The First People's Hospital of Lianyungang
Recruiting - verified January 2012 - Conditions: Advanced Cancers; Colorectal Cancer; Head And Neck Cancer; Cancer Survivors
Interventions: Device: Smart phone; Device: Accelerometers (Arms 1 and 2); Device: Blood Pressure Monitor (Arms 1 and 2); Other: Telephone Surveys; Other: Home Visit; Device: Home Health Hub and Modem (All study groups); Device: Carbon Monoxide (CO) Monitor (Arm 4); Device: Heat Rate Monitor (Arm 1); Device: Global Positioning System (GPS) Device (Arm 1); Other: Surveys
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer
Intervention: Drug: linifanib
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Metastatic Breast Cancer; Liver Metastases
Intervention: Drug: oxaliplatin, capecitabine, trastuzumab
Sponsors: Herlev Hospital; Herlev Hospital; Odense University Hospital; Aarhus University Hospital
Recruiting - verified April 2010 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: M0003 (SPD557); Drug: placebo
Sponsors: Movetis; Movetis
Active, not recruiting - verified October 2011 - Conditions: Solid Tumor; Colorectal Cancer; Endometrial Cancer
Intervention: Drug: DS-7423
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012 - Condition: Metastatic Colorectal Cancer
Intervention:
Sponsors: Azienda Ospedaliero, Universitaria Pisana; Azienda Ospedaliero, Universitaria Pisana
Recruiting - verified May 2011 - Condition: Colorectal Cancer
Intervention: Other: Eligible patients' paper-based reminder
Sponsors: Paris 12 Val de Marne University; Paris 12 Val de Marne University
Active, not recruiting - verified May 2011 - Conditions: Metastatic Breast Cancer; Liver Metastases
Intervention: Drug: oxaliplatin, capecitabine, trastuzumab
Sponsors: Herlev Hospital; Herlev Hospital; Odense University Hospital; Aarhus University Hospital
Recruiting - verified April 2010 - Condition: Rectal Cancer
Intervention: Drug: Therapeutic target tailored chemotherapy
Sponsors: Grupo Hospital de Madrid; Grupo Hospital de Madrid
Completed - verified October 2009 - Condition: Gastric Cancer
Intervention: Drug: Trastuzumab+Capecitabine+Oxaliplatin
Sponsors: Peking University; Peking University
Recruiting - verified March 2011 - Condition: Crohn's Disease
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified May 2011
 |
Join Clinical Trials in Quebec Canada |
